<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0908222439
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PRINCEOXIN 250 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        17
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>PRINCEOXIN is in a group of antibiotics called quinolones (kwin-o-lones) that:</strong></p><ul><li>Stop growth of bacteria.</li><li>Kill the bacteria.</li><li>Reduce the infection.</li></ul><p>&nbsp;</p><p><strong>PRINCEOXIN is used to treat bacterial infections in the:</strong></p><ul><li>Skin.</li><li>Kidneys.</li><li>Urinary tract (bladder or prostate).</li><li>Sinuses.</li><li>Lungs.</li></ul><p>Some infections are caused by viruses, such as the common cold. PRICNEOXIN does not kill viruses.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Serious Warnings and Precautions</strong></p><p>Talk to your doctor, before taking PRINCEOXIN if you:</p><ul><li>Have serious allergic reaction to levofloxacin or similar antibiotics such as ciprofloxacin, moxifloxacin, and others</li><li>Have seizures (convulsions). Tell your doctor if you have any problems in the brain, including epilepsy. Your doctor will tell you whether you should use this medication.</li><li>Have muscle problems (e.g. weakness, joint problems). <strong>Do not use </strong>levofloxacin if <strong>you have or have had </strong>myasthenia gravis.</li><li>Have previous history of inflamed tendon (fiber that connects bones to muscles in the body) and tendon rupture. Your risk for tendon problem is greater, if you are over 60 years of age, and if you are taking steroid medication, or if you have had kidney, heart or lung transplant.</li><li>Have family history of long QT syndrome (Prolongation of the heartbeat on an electrocardiogram test).</li><li>If you have been diagnosed with an enlargement or &quot;bulge&quot; of a large blood vessel (aortic aneurysm or large vessel peripheral aneurysm).</li><li>If you have experienced a previous episode of aortic dissection (a tear in the aorta wall).</li><li>If you have a family history of aortic aneurysm or aortic dissection or other risk factors&nbsp; predisposing conditions (e.g. connective tissue disorders such as Marfan syndrome, or vascular Ehlers-Danlos syndrome, or vascular disorders such as Takayasu arteritis, giant cell arteritis, Behcet&#39;s disease, high blood pressure, or known atherosclerosis).</li></ul><p>If you feel sudden, severe pain in your abdomen, chest or back, go immediately to an emergency room.</p><p>&nbsp;</p><p><strong><u>b- Take special care with </u></strong><strong><u>PRINCEOXIN:</u></strong></p><p><strong>Do not use </strong>PRICNEOXIN<strong> if:</strong></p><ul><li>You have allergic reaction to this drug &nbsp;or to other quinolone antibiotics (such as ciprofloxacin, moxifloxacin)<strong>.</strong></li><li>You have a history of tendinitis (inflammation of tendon or tendon rupture). This condition causes pain and tenderness just outside of joint in shoulders, elbows, wrists, knees, heels, etc.</li></ul><p>&nbsp;</p><p><strong>To help avoid side effects and ensure proper use, talk to your healthcare professional before you take PRICNEOXIN. Talk about any health conditions or problems you may have, including if you:</strong></p><ul><li>have kidney problems.</li><li>have epilepsy.</li><li>have or have had a seizures (convulsions).</li><li>have had any problems with your heart rhythm, heart rate, or problems with low potassium.</li><li>have a diabetes and are taking anti-diabetic medication (it may interfere with blood sugar levels).</li><li>have a disease that causes muscle weakness (myasthenia gravis).</li><li>experience any symptoms of muscle weakness, including breathing difficulties (e.g., shortness of breath).</li><li>have a history of tendon problems associated with antibiotics.</li><li>are pregnant or plan to become pregnant.</li><li>are breastfeeding or plan to breastfeed. Talk to your doctor about how to feed your baby while you are taking PRICNEOXIN.</li></ul><p>&nbsp;</p><p><strong>Other warnings you should know about:</strong></p><p>Changes in Blood Sugar:</p><p>If you have diabetes, you may develop a hypoglycemic reaction (low blood sugar) with common symptoms such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive hunger.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lack of coordination.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting.</p><p>or a <strong>hyperglycemic reaction </strong>(high blood sugar) with common symptoms such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive thirst.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive urination.</p><p>&nbsp;</p><p><strong>You should call your doctor if you experience any of these symptoms.</strong></p><p>Allergic Reaction:</p><p>If you develop one of the following:</p><p>-Hives.</p><p>-Itching.</p><p>-Skin rash.</p><p>-Difficulty breathing or swallowing.</p><p>-Swelling in the face, tongue or throat.</p><p>-Other symptoms of an allergic reaction.</p><p>&nbsp;</p><p><strong>Protect your skin from sunlight</strong></p><p>You should not expose yourself to sunlight or artificial ultraviolet light while you are taking PRINCEOXIN. Use sunscreen and wear protective clothing if out in the sun.</p><p>&nbsp;</p><p>Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.</p><p>&nbsp;</p><p><strong><u>c- Using other medicines, herbal or dietary supplements:</u></strong></p><p>&nbsp;</p><ul><li>antacids, multi-vitamins, or products containing metals (such as aluminum, calcium, iron, magnesium or zinc). See How to take PRINCEOXIN.</li><li>medicines used for ulcers (such as sucralfate). See How to take PRINCEOXIN.</li><li>medicines used for heartburn or gout (such as probenecid, cimetidine, etc).</li><li>medicines used for treatment of asthma or chronic obstructive pulmonary disease (COPD) (such as theophylline).</li><li>medications for arthritis (nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen).</li><li>blood sugar medicines (such as metformin, gliclazide, insulin,etc).</li><li>medicines used for any heart conditions.</li><li>blood thinner medications (such as warfarin, etc.) that used to thin the blood and prevent clots &ndash; may predispose you to the development of bleeding problems.</li></ul><p><strong>This medication may interfere with certain laboratory tests (such as urine screening for opiates), possibly causing false test results.</strong></p><p><strong>Urine test for Opiates</strong></p><p>Urine tests may give false-positive results for strong pain killers known as opiates if you are taking PRINCEOXIN. If you are taking PRINCEOXIN, tell your doctor before your test.</p><p>&nbsp;</p><p><strong>Taking PRINCEOXIN with alcohol</strong></p><p>Do not drink alcohol while taking PRINCEOXIN.</p><p>&nbsp;</p><p><strong><u>e. Pregnancy and breast-feeding</u></strong></p><p>Levofloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p><p>Because of the potential for serious Undesirable effects from levofloxacin in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p><strong><u>f- Driving and using machines:</u></strong></p><p>Operating Heavy Machinery:</p><p>You should know that use of PRINCEOXIN may cause dizziness. Please make sure that you know how to react if you are:</p><p>-driving a car.</p><p>-operate any machinery at working place.</p><p>-perform work that needs mental alertness or coordination.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You should swallow the whole tablet with or without food.</p><p>Try to take the tablet at the same time and drink plenty of fluids while taking this medicine unless otherwise directed by your doctor.</p><p>Do not share your medicine with anyone.</p><p>&nbsp;</p><p>Antibacterial drugs like <em>PRINCEOXIN</em> treat only bacterial infections. They do not treat viral infections. Although you may feel better early in the treatment, <em>PRINCEOXIN</em> should be used exactly as directed.</p><p>&nbsp;</p><p>Misuse or overuse of <em>PRINCEOXIN</em> could lead to the growth of bacterial that will not be killed by <em>PRINCEOXIN</em> (resistance). This means that <em>PRINCEOXIN</em> may not work in the future.</p><p>&nbsp;</p><p>Ask your pharmacist about the other products you take. Some medicines will affect the way that your body absorbs <em>PRINCEOXIN</em>. Take <em>PRINCEOXIN</em> at least 2 hours before or 2 hours after taking these medicines. Some examples include: vitamins/minerals (including iron and zinc supplements), and products containing magnesium, aluminum, or calcium (such as antacids, calcium supplements).</p><p>&nbsp;</p><p><strong>Usual adult dose:</strong></p><p>You should take this medication by mouth as directed by your doctor.</p><p>&nbsp;</p><p>The dosage and length of the treatment depends on your kidney function, medical condition, and response to treatment. It may last for 3, 5, 7, 10, 14 or 28 days depending on your condition.</p><p>&nbsp;</p><p><strong>Tell your doctor if your condition does not improve.</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>a- If you take more PRINCEOXIN than you should:</u></strong></p><p>If you think you have taken too much <em>PRINCEOXIN</em>, contact your healthcare professional, hospital emergency department or regional poison control center immediately, even if there are no symptoms.</p><p>Symptoms of overdose may include: severe dizziness</p><p>&nbsp;</p><p><strong><u>b- If you forget to use PRINCEOXIN:</u></strong></p><p>If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.</p><p>&nbsp;</p><p><strong><u>c- If you stop using PRINCEOXIN:</u></strong></p><p>Do not stop taking PRINCEOXIN tablets just because you feel better. It is important that you complete the course of tablets that your doctor has prescribed for you. If you stop taking the tablets too soon, the infection may return, your condition may get worse or the bacteria may become resistant to the medicine.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>These are not all the possible side affects you may feel when taking <em>PRINCEOXIN</em>. If you experience any side effects not listed here, contact your healthcare professional.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top" colspan="6"><p><strong>Serious side effects and what to do about them</strong></p></td></tr><tr><td style="vertical-align:top" rowspan="2" colspan="2"><p>&nbsp;</p><p>Symptom / effect</p></td><td style="vertical-align:top" colspan="2"><p>Talk to your &nbsp;healthcare professional</p></td><td style="vertical-align:top" rowspan="2" colspan="2"><p>Stop taking drug and get immediate medical help</p></td></tr><tr><td style="vertical-align:top"><p>Only if severe</p></td><td style="vertical-align:top"><p>In all cases</p></td></tr><tr><td style="vertical-align:top" colspan="6"><p><strong>VER</strong><strong>Y COMMON</strong></p></td></tr><tr><td style="vertical-align:top" colspan="2"><p>Nausea</p></td><td style="vertical-align:top"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p>Headache</p></td><td style="vertical-align:top"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p>Diarrhea (having slightly soft to watery stool)</p></td><td style="vertical-align:top"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p>Insomnia (lack of sleep)</p></td><td style="vertical-align:top"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p>Dizziness (drowsiness, light-headedness)</p></td><td style="vertical-align:top"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p>Constipation (hard to pass stool).</p></td><td style="vertical-align:top"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="6"><p><strong>COMMON</strong></p></td></tr><tr><td style="vertical-align:top" colspan="2"><p>Abdominal or stomach pain or discomfort.</p></td><td style="vertical-align:top"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p>Vomiting.</p></td><td style="vertical-align:top"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p>Dyspepsia&nbsp; (discomfort&nbsp;or&nbsp;pain&nbsp;in the upper abdomen).</p></td><td style="vertical-align:top"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p>Dyspnea (shortness of breath).</p></td><td style="vertical-align:top"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p>Moniliasis&nbsp; (yeast&nbsp;infection&nbsp;of&nbsp;the mouth and throat).</p></td><td style="vertical-align:top"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p>Skin rash.</p></td><td style="vertical-align:top"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p>Pruritus (itching).</p></td><td style="vertical-align:top"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p>Vaginal itching and discharge.</p></td><td style="vertical-align:top"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p>Edema (swelling caused by excess fluid in your body).</p></td><td style="vertical-align:top"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p>Chest pain.</p></td><td style="vertical-align:top"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="6"><p><strong>RARE</strong></p></td></tr><tr><td style="vertical-align:top"><p>Stomach cramps or pain (severe)</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Agitation (purposeless movements)</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blisters</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>confusion</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>diarrhea (watery and severe) which may also be bloody</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>feeling that others can hear your thoughts or control your behavior</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>fever</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>pain, inflammation, or swelling in the calves of the legs, shoulders, or hands, including tendon rupture or swelling of the tendon (tendinitis)</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>redness and swelling of the skin</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>seeing, hearing, or feeling things that are not there</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>sensation of burning on the skin</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>severe mood or mental changes</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Neuropathy (problems in the nerves such as pain, burning, tingling, numbness or weakness)</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>skin rash, itching, or redness &ndash; sun sensitivity (photosensitivity), which can appear as skin eruption or severe sunburn</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>trembling</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>unusual behavior</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>severe/persistent headache</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top"><p>✔</p></td></tr><tr><td style="vertical-align:top"><p>vision changes</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top"><p>✔</p></td></tr><tr><td style="vertical-align:top"><p>Shaking (tremors), seizures (convulsions)</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top"><p>✔</p></td></tr><tr><td style="vertical-align:top"><p>severe dizziness, fainting</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top"><p>✔</p></td></tr><tr><td style="vertical-align:top"><p>fast/irregular heartbeat</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top"><p>✔</p></td></tr><tr><td style="vertical-align:top"><p>mental/mood changes (such as nervousness, confusion, hallucinations, depression, rare thoughts of suicide)</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top"><p>✔</p></td></tr><tr><td style="vertical-align:top"><p>signs of liver problems (such as persistent nausea/vomiting, stomach/abdominal pain, unusual tiredness, yellowing eyes/skin, dark urine)</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top"><p>✔</p></td></tr></tbody></table><p>If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep out of the reach and sight of children.</p><p>- Store below 30&deg;C.</p><p>- Store in the original package in order to protect from light.</p><p>Do not use PRINCEOXIN after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>a- What the medicinal ingredient is:</u></strong></p><ul><li>The active substance is levofloxacin hemihydrate.</li><li>The other ingredients are croscarmellose sodium, methylcellulose (E461), stearic acid (E570), magnesium stearate (E572), colloidal silicon dioxide, hypromellose (E464), hydroxypropylcellulose type LF (E463), macrogol 8000, titanium dioxide (E171), yellow ferric oxide (only with 500 mg), and red ferric oxide (only with 250mg &amp; 500mg)</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                PRINCEOXIN 250 mg:  Tablets are supplied as terra cotta pink, capsule- shaped, biconvex, film-coated tablets. Engraved “APO” on one side and “LFX 250” on the other side.
PRINCEOXIN 500 mg:  500 mg Tablets are supplied as peach, capsule-shaped, biconvex, film-coated tablets. Engraved “APO” on one side and “LFX 500” on the other side.
PRINCEOXIN 750 mg: Tablets are supplied as white to off-white, capsule-shaped, biconvex, film-coated tablets. Engraved “APO” on one side and “LFX 750” on the other side.

•	The tablets are available in blister packs of 5 and 10 tablets. 
•	Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Last revised on 12/2018.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>&nbsp;برينسيوكسين هو عبارة عن مجموعة من المضادات الحيوية تدعى الكينولونات والتي تعمل على:</strong></p><ul dir="rtl"><li>وقف نمو البكتريا.</li><li>قتل البكتريا.</li><li>الحد من العدوى.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يستخدم برينسيوكسين في علاج العدوى البكتيرية التي تصيب:</strong></p><ul dir="rtl"><li>الجلد.</li><li>الكليتان.</li><li>المسالك البولية (المثانة أو البروستاتا).</li><li>الجيوب الأنفية.</li><li>الرئتان.</li></ul><p dir="RTL">تتسبب الفيروسات في الإصابة ببعض أنواع العدوى، مثل نزلات البرد. لا يقتل برينسيوكسين الفيروسات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><u>أ. لا تتناول برينسيوكسين</u></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات المهمة</strong></p><p dir="RTL">تحدّث مع الطبيب، قبل تناول برينسيوكسين في حالة:</p><ul dir="rtl"><li>إذا كان لديك حساسية لليفوفلوكساسين أو المضادات الحيوية المماثلة مثل سيبروفلوكساسين، وموكسيفلوكساسين، وغيرها.</li><li>إذا كان لديك نوبات (تشنجات). أخبر الطبيب إذا كان لديك أية مشاكل في الدماغ، بما في ذلك الصرع، وسوف يخبرك الطبيب إذا كان ينبغي عليك استخدام هذا الدواء.</li><li>إذا كان لديك مشاكل في العضلات (مثل الضعف ومشاكل المفاصل). <strong>لا تستخدم</strong> الليفوفلوكساسين إذا كنت تعاني أو عانيت في وقت سابق من الوهن العضلي الوبيل.</li><li>لديك تاريخ سابق من التهاب الأوتار (الألياف التي تربط العظام بالعضلات في الجسم) وتمزق الأوتار. يزداد خطر الإصابة بمشكلة الأوتار، إذا كان عمرك أكثر من 60 عامًا، وإذا كنت تتناول دواء الستيرويد، أو إذا كنت أجريت عملية زرع للكلى أو القلب أو الرئة.</li><li>إذا كان لديك تاريخ عائلي من متلازمة فترة QT الطويلة (إطالة ضربات القلب عند إجراء رسم القلب الكهربائي).</li><li>إذا تمّ تشخيصك بالإصابة بتضخم أو &quot;انتفاخ&quot; أحد الأوعية الدموية الكبيرة (أم الدم الأبهري، أو أم الدم الوعائي المحيطي الكبير).</li><li>إذا كنت قد عانيت من نوبة سابقة من تسلخ الشريان الأبهر (تمزق في جدار الشريان الأبهر).</li><li>إذا كان لديك تاريخ عائلي من أم الدم الأبهرية، أو تسلخ الشريان الأبهر، أو عوامل الخطر الأخرى التي تمهد للإصابة بالأمراض (على سبيل المثال اضطرابات النسيج الضام مثل متلازمة مارفان، أو متلازمة إهلرز-دانلوس، أو اضطرابات الأوعية الدموية مثل التهاب الشرايين تاكاياسو، أو التهاب الشريان الخلوي العملاق، أو مرض بهجت، أو ارتفاع ضغط الدم، أو تصلب الشرايين المعروف).</li></ul><p dir="RTL">إذا شعرت بألم حاد ومفاجئ في البطن أو الصدر أو الظهر، فاتجه على الفور إلى غرفة الطوارئ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناول برينسيوكسين إذا كنت تعاني من:</p><ul dir="rtl"><li>ردّ فعل تحسسي تجاه هذا الدواء أو المضادات الحيوية الأخرى من فئة الكينولونات (مثل سيبروفلوكساسين، وموكسيفلوكساسين).</li><li>تاريخ من التهاب الأوتار (التهاب الأوتار أو تمزق الأوتار). &nbsp;يسبب هذا المرض ألمًا وإيلامًا عند اللمس خارج المفصل مباشرة في الكتفين والمرفقين والرسغين والركبتين والكعبين،... إلخ.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لتجنب هذه الآثار الجانبية والتأكد من استخدام الدواء بشكل سليم، تحدّث إلى اختصاصي الرعاية الصحية قبل تناول برينسيوكسين، وأخبر الطبيب بأية حالة أو مشكلة صحية قد تعاني منها بما في ذلك إذا كنت:</strong></p><ul dir="rtl"><li>تعاني من مشاكل في الكلى.</li><li>تعاني من الصرع.</li><li>تتعرض أو تعرضت سابقًا لنوبات (تشنجات).</li><li>عانيت من أية مشكلات في نظم القلب أو معدل ضربات القلب أو مشكلات انخفاض البوتاسيوم.</li><li>مصابًا بداء السكري وتتناول مضادات السكري (قد تتداخل مع مستويات السكر في الدم).</li><li>تعاني من مرض يسبب ضعف العضلات (الوهن العضلي الوبيل).</li><li>عانيت من أي أعراض مرض ضعف العضلات، بما في ذلك صعوبات التنفس (على سبيل المثال ضيق التنفس).</li><li>لديك تاريخ من مشكلات الأوتار المرتبط بالمضادات الحيوية.</li><li>حاملًا أو تخططين للحمل.</li><li>ترضعين أو تخططين للرضاعة الطبيعية. تحدثي إلى الطبيب حول كيفية إطعام طفلك في أثناء تناولك برينسيوكسين.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات الأخرى التي ينبغي معرفتها:</strong></p><p dir="RTL">تغيرات في نسبة السكر في الدم:</p><p dir="RTL">إذا كنت مصابًا بداء السكري، فقد يتطور إلى رد فعل في صورة انخفاض سكر الدم (سكر الدم المنخفض) بالإضافة إلى أعراض شائعة مثل:</p><ul dir="rtl"><li>الدوخة.</li><li>الجوع المفرط.</li><li>عدم الاتساق.</li><li>صداع.</li><li>إعياء.</li><li>إغماء.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">أو <strong>رد فعل في صورة فرط سكر الدم</strong> (ارتفاع سكر الدم) بالإضافة إلى أعراض شائعة مثل:</p><ul dir="rtl"><li>العطش المفرط.</li><li>التبول المفرط.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ينبغي عليك الاتصال بالطبيب إذا كنت تعاني من أي من هذه الأعراض.</strong></p><p>رد الفعل التحسسي:</p><p>إذا تطورت لديك أيّ من هذه الأعراض:</p><ul dir="rtl"><li>الشرى.</li><li>الحكة.</li><li>الطفح الجلدي.</li><li>صعوبة في التنفس أو البلع.</li><li>تورم في الوجه أو اللسان أو الحلق.</li><li>أعراض أخرى لرد الفعل التحسسي.</li></ul><p>&nbsp;</p><p dir="RTL"><strong>احم بشرتك من أشعة الشمس</strong></p><p dir="RTL">ينبغي عدم التعرض لأشعة الشمس أو للأشعة فوق البنفسجية الاصطناعية في أثناء تناولك برينسيوكسين. استخدم واقٍ من الشمس وارتدِ ملابس واقية في أثناء تعرضك لأشعة الشمس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر اختصاصي الرعاية الصحية عن جميع الأدوية التي تتناولها، بما في ذلك أي عقاقير أو فيتامينات أو معادن أو مكملات غذائية أو أدوية بديلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ج- تناوُل أدوية أخرى أو المستحضرات النباتية أو المكملات الغذائية:</u></strong></p><ul dir="rtl"><li>مضادات الحموضة، أو التركيبات متعددة الفيتامينات، أو المنتجات التي تحتوي على معادن (مثل الألومنيوم أو الكالسيوم أو الحديد أو المغنسيوم أو الزنك). انظر قسم كيفية تناول برينسيوكسين.</li><li>الأدوية التي تُستخدم لعلاج القرحة (مثل سوكرالفات). انظر قسم كيفية تناول برينسيوكسين.</li><li>الأدوية التي تُستخدم لعلاج حرقة المعدة أو النقرس (مثل بروبنيسيد، وسيميتيدين، وغيرها).</li><li>الأدوية التي تُستخدم لعلاج الربو، أو مرض الانسداد الرئوي المزمن (مثل ثيوفيلين).</li><li>الأدوية التي تُستخدم لعلاج التهاب المفاصل (أدوية مضادات الالتهاب غير الاستيرودية) مثل إيبوبروفين، ونابروكسين.</li><li>أدوية سكر الدم (مثل ميتفورمين، وجليكلازيد، والأنسولين، وغيرها).</li><li>الأدوية التي تُستخدم لعلاج أمراض القلب.</li><li>أدوية تخفيف الدم (مثل الوارفارين وغيرها) التي تُستخدم لتسييل الدم أو منع التجلطات - قد تجعلك عرضة للإصابة بمشكلات النزيف.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يتداخل هذا الدواء مع اختبارات معملية محددة (مثل تحليل المخدرات في البول)، ومن المحتمل أن يؤدي إلى ظهور نتائج خاطئة.</strong></p><p dir="RTL"><strong>تحليل المخدرات في البول</strong></p><p dir="RTL">قد تظهر تحليلات البول نتائج إيجابية خاطئة عن وجود مسكنات الألم القوية التي تدعى الأفيونات في حالة تناول برينسيوكسين. إذا كنت تتناول برينسيوكسين فأخبر الطبيب قبل إجراء الاختبار.</p><p dir="RTL"><strong>برينسيوكسين مع الكحول</strong></p><p dir="RTL">لا تتناول المشروبات الكحولية في أثناء العلاج باستخدام برينسيوكسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>د. الحمل والرضاعة الطبيعية:</u></strong></p><p dir="RTL">ينبغي عدم تناول ليفوفلوكساسين في أثناء الحمل إلا إذا كانت الفوائد المحتملة تبرر المخاطر المتوقعة على الجنين.</p><p dir="RTL">ونظرًا لاحتمالية أن يتسبب ليفوفلوكساسين في حدوث آثار خطيرة غير مرغوب بها على الرضع، فينبغي اتخاذ القرار بشأن ما إذا كان يتعين وقف الرضاعة الطبيعية أم وقف الدواء بعد أن يؤخذ في الاعتبار أهمية الدواء بالنسبة للأم.</p><p dir="RTL">استشيري الطبيب أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ه- القيادة واستخدام الآلات:</u></strong></p><p dir="RTL">تشغيل الآلات الثقيلة:</p><p dir="RTL">ينبغي عليك معرفة أن استخدام برينسيوكسين قد يسبب الدوخة. يُرجى التأكد من أنك تعرف كيف تتصرف في حالة:</p><ul dir="rtl"><li>قيادة سيارة.</li><li>تشغيل أية آلة في مكان العمل.</li><li>أداء الأعمال التي تتطلب يقظة عقلية أو تنسيق.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ينبغي ابتلاع القرص بالكامل مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;حاول تناول القرص في التوقيت نفسه، واحرص على شرب كمية كبيرة من السوائل في أثناء الخضوع لهذا العلاج ما لم يوصِ الطبيب بغير ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تشارك الدواء الخاص بك مع أي شخص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأدوية المضادة للبكتريا، مثل برينسيوكسين لا تستخدم سوى لعلاج العدوى البكتيرية ولا تستخدم لعلاج العدوى الفيروسية. وعلى الرغم من أنك قد تشعر بتحسن مبكر مع العلاج، ينبغي استخدام برينسيوكسين وفقًا للجرعة الموصى بها تمامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن إساءة الاستخدام أو الاستخدام المفرط لـ برينسيوكسين يمكن أن يؤدي إلى نمو بكتريا يصعب على برينسيوكسين قتلها (مقاومتها). وهذا يعني أنه قد لا يمكن استخدام برينسيوكسين في المستقبل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اسأل الصيدلي عن المنتجات الأخرى التي تتناولها. فبعض الأدوية قد تؤثر على طريقة امتصاص جسمك لـ برينسيوكسين. تناول برينسيوكسين قبل تناول هذه الأدوية أو بعد ساعتين على الأقل. قد تتضمن بعض الأمثلة: الفيتامينات/ المعادن (بما في ذلك مكملات الحديد والزنك)، والمنتجات التي تحتوي على المغنسيوم أو الألومنيوم أو الكالسيوم (مثل مضادات الحموضة، ومكملات الكالسيوم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة العادية للبالغين:</strong></p><p dir="RTL">ينبغي تناول هذا الدواء عن طريق الفم وفقًا لتعليمات الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعتمد الجرعة وطول مدة العلاج على وظائف الكلى وحالتك الطبية ومدى استجابتك للعلاج. قد تستمر مدة العلاج لمدة 3 أو 5 أو 7 أو 10 أو 14 أو 28 يومًا وفقًا لحالتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر الطبيب إذا لم تشهد تحسُّنًا في حالتك.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><u>أ- إذا تناولت برينسيوكسين أكثر مما يجب:</u></strong></p><p dir="RTL">إذا كنت تعتقد أنك تناولت أكثر مما ينبغي من برينسيوكسين، فاتصل باختصاصي الرعاية الصحية أو قسم الطوارئ بالمستشفى أو مركز مكافحة السموم على الفور، حتى لو لم تظهر أي أعراض.</p><p dir="RTL">قد تشمل أعراض الجرعة الزائدة الدوخة الشديدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ب- إذ نسيت تناول برينسيوكسين</u></strong>:</p><p dir="RTL">إذا نسيت تناول برينسيوكسين فتناوله بمجرد أن تتذكره. إذا اقترب موعد الجرعة التالية فلا تتناول الجرعة المنسية واستكمل جدول الجرعات كالمعتاد. لا تتناول جرعة مزدوجة للتعويض عن الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ج- إذا توقفت عن تناول برينسيوكسين:</u></strong></p><p dir="RTL">لا تتوقف عن تناول أقراص برينسيوكسين لمجرد شعورك بتحسن. من المهم استكمال مدة العلاج التي وصفها لك الطبيب. إذا توقفت عن العلاج في وقت قريب جدًا، فقد تعاود العدوى الظهور مرة أخرى، وقد تسوء حالتك أو قد تقاوم البكتريا العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، فاسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تشمل هذه القائمة جميع الآثار الجانبية المحتملة التي قد تشعر بها في أثناء تناولك برينسيوكسين. إذا شعرت بأي أعراض جانبية غير مدرجة في هذه النشرة، فاتصل بأخصائي الرعاية الصحية.</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top" colspan="6"><p dir="RTL"><strong>الأعراض الجانبية </strong><strong>الخطيرة</strong><strong> </strong><strong>وماذا تفعل حيالها</strong></p></td></tr><tr><td style="vertical-align:top" rowspan="2" colspan="2"><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض/ الآثار</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">تحدّث مع اختصاصي الرعاية الصحية</p></td><td style="vertical-align:top" rowspan="2" colspan="2"><p dir="RTL">توقف عن تناول الدواء واحصل على المساعدة الطبية فورًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إذا كانت شديدة فقط</p></td><td style="vertical-align:top"><p dir="RTL">في جميع الحالات</p></td></tr><tr><td style="vertical-align:top" colspan="6"><p dir="RTL"><strong>شائعة </strong><strong>جدًّ</strong><strong>ا</strong></p></td></tr><tr><td style="vertical-align:top" colspan="2"><p dir="RTL">غثيان.</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p dir="RTL">صداع.</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p dir="RTL">إسهال (براز لين إلى حد ما إلى البراز المائي).</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p dir="RTL">الأرق (نقص النوم).</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p dir="RTL">دوخة (نعاس، دوار خفيف).</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p dir="RTL">إمساك (براز صعب الخروج).</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="6"><p dir="RTL"><strong>شائعة</strong></p></td></tr><tr><td style="vertical-align:top" colspan="2"><p dir="RTL">ألم البطن أو ألم المعدة أو عدم الراحة.</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p dir="RTL">قيء.</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p dir="RTL">عسر الهضم (عدم الراحة أو ألم في الجزء العلوي من البطن).</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p dir="RTL">ضيق التنفس (قصر النفس).</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p dir="RTL">داء المبيضات (عدوى فطرية بالفم والحلق).</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p dir="RTL">طفح جلدي.</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p dir="RTL">حكة (هرش).</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p dir="RTL">حكة المهبل وإفرازات مهبلية.</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p dir="RTL">وذمة (تورم ناتج عن زيادة السوائل في جسمك).</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p dir="RTL">ألم في الصدر.</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top" colspan="6"><p dir="RTL"><strong>نادرة</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تشنجات أو ألم في المعدة (شديدة).</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">هياج (حركة عشوائية).</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">بثور.</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ارتباك.</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إسهال (مائي وشديد) قد يكون دمويًّا أيضًا.</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الشعور بأن الآخرين يمكنهم سماع أفكارك أو السيطرة على سلوكك.</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">حمى.</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ألم أو التهاب أو تورم في ربلة الساقين أو الكتفين أو اليدين بما في ذلك تمزق الأوتار أو تورم الأوتار (التهاب الأوتار).</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">احمرار البشرة وتورمها.</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">رؤية أو سماع أو الشعور بأشياء غير موجودة.</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إحساس بحرق على الجلد.</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تقلبات مزاجية أو عقلية شديدة.</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الاعتلال العصبي (مشكلات في الأعصاب مثل الألم أو الحرق أو الوخز أو الخدر أو الضعف).</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الطفح الجلدي أو الحكة أو الاحمرار &ndash; حساسية الشمس (حساسية الضوء) والتي يمكن أن تظهر في شكل تهيج الجلد أو حروق الشمس الشديدة.</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الارتجاف.</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">سلوك غير معتاد.</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">✔</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">صداع شديد/ مستمر.</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تغيرات في الرؤية.</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">رعشة (هزات)، نوبات (تشنجات).</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">دوار شديد وإغماء.</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ضربات قلب سريعة/غير منتظمة.</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تغيرات عقلية/ مزاجية (مثل العصبية، والارتباك، والهلوسة، والاكتئاب، وأفكار انتحارية نادرة).</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">علاماتعلى وجود مشكلات بالكبد (مثل الغثيان/ القيء المستمر، وألم في البطن/المعدة، وإيلام غير عادي عند اللمس، واصفرار العينين /البشرة، وبول داكن).</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">✔</p></td></tr></tbody></table><p dir="RTL">إذا شهدت أي أعراض أو آثار جانبية مزعجة غير مدرجة هنا، أو تطورت حدة أي منها إلى حد يعيق أنشطتك اليومية، فأخبر اختصاصي الرعاية الصحية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul dir="rtl"><li>يُحفظ بعيدًا عن متناول الأطفال.</li><li>يُحفظ في درجة حرارة أقل من 30 درجة مئوية.</li><li>يُحفظ في العبوة الأصلية لحمايته من الضوء.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم برينسيوكسين بعد تاريخ انتهاء الصلاحية المدون على العبوة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي دواء عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. سوف تساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><u>أ- ما مكونات الدواء:</u></strong></p><ul dir="rtl"><li>المادة الفعالة هي ليفوفلوكساسين هيميهيدرات.</li><li>المواد الأخرى هي كروس كارميلوز الصوديوم، ميثيل السليولوز (E461)، حمض الستياريك (E570)، ستيرات المغنسيوم (E572)، ثنائي أوكسيد السيليكون الغروي، هيبروميلوز (E464)، هيدروكسي بروبيل السليلوز فئة ال اف (E463)، ماكروغول 8000، ثاني أكسيد التيتانيوم (E171)، أكسيد الحديديك الأصفر (أقراص 500 ملغ فقط)، أكسيد الحديديك الأحمر (أقراص 250 ملغ و500 ملغ فقط)</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>برينسيوكسين </u><u>250</u><u> ملغ</u>: أقراص باللون الزهري التيراكوتا كبسولية الشكل محدبة الوجهين ومغلفة محفور عليها &quot;APO&quot; على جانبٍ واحد و&quot;LFX 250&quot; على الجانب الآخر.</p><p dir="RTL"><u>برينسيوكسين </u><u>500</u><u> ملغ</u>: أقراص 500 ملغ بلون الخوخ كبسولية الشكل محدبة الوجهين ومغلفة. محفور عليها &quot;APO&quot; على جانبٍ واحد و&quot;LFX 500&quot; على الجانب الآخر.</p><p dir="RTL"><u>برينسيوكسين </u><u>750</u><u> ملغ:</u> أقراص يتراوح لونها بين الأبيض إلى الأبيض الفاتح كبسولية الشكل محدبة الوجهين ومغلفة. محفور عليها ا&quot;APO&quot; على جانب واحد و&quot;LFX 750&quot; على الجانب الآخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot; الأقراص متاحة في أشرطة ذات غلاف بلاستيكي تحتوي على 5 و10 أقراص.</p><p dir="RTL"><em>&middot;&nbsp;</em>قد لا تكون جميع الأحجام متوفرة في السوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أبوتكس إنك، تورنتو، M9L 1T9 كندا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Trade Name in the GCC States: Princeoxin
Trade Name in the Country of Origin: Apo-Levofloxacin
Generic Name: Levofloxacin
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Route of Administration: Oral

Dosage Form / Strength: Tablet / 250 mg, 500 mg and 750 mg

All Nonmedicinal Ingredients: croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, methylcellulose, stearic acid, hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyethylene glycol, titanium dioxide, red ferric oxide (250 mg
and 500mg), yellow ferric oxide (500 mg)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Princeoxin (Levofloxacin) 250 mg Tablets are supplied as terra cotta pink, capsule- shaped, biconvex, film-coated tablets. Engraved “APO” on one side and “LFX 250” on the other side.

Princeoxin (Levofloxacin) 500 mg Tablets are supplied as peach, capsule-shaped, biconvex, film-coated tablets. Engraved “APO” on one side and “LFX 500” on the other side.

Princeoxin (Levofloxacin) 750 mg Tablets are supplied as white to off-white, capsule-shaped, biconvex, film-coated tablets. Engraved “APO” on one side and “LFX 750” on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PRINCEOXIN tablets are indicated for the treatment of adults with bacterial infections caused by susceptible strains of the designated microorganisms in the infections listed below.</p><p>&nbsp;</p><p><strong>Upper</strong><strong> </strong><strong>Respiratory</strong><strong> </strong><strong>Tract</strong></p><p>Acute sinusitis (mild to moderate) due to <em>Streptococcus pneumoniae, Haemophilus influenzae, </em>or&nbsp;<em>Moraxella (Branhamella) catarrhalis.</em></p><p><strong><em>&ldquo;Restrict</em></strong><strong><em> </em></strong><strong><em>the</em></strong><strong><em> </em></strong><strong><em>use</em></strong><strong><em> </em></strong><strong><em>of PRINCEOXIN to settings where no other treatment options exist, and the clinical presentation meets the diagnostic criteria for acute bacterial sinusitis.&rdquo;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong>Lower</strong><strong> </strong><strong>Respiratory Tract</strong></p><p>Acute bacterial exacerbations of chronic bronchitis (mild to moderate) due to <em>Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, </em>or <em>Moraxella (Branhamella) catarrhalis.</em></p><p>&nbsp;</p><p>Community-acquired pneumonia (mild, moderate and severe infections) due to <em>Staphylococcus aureus, Streptococcus pneumoniae </em>(including penicillin-resistant strains), <em>Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella (Branhamella) catarrhalis, Chlamydia pneumoniae, Legionella pneumophila, </em>or <em>Mycoplasma pneumoniae </em><strong>(see DOSAGE AND ADMINISTRATION, and <em>Product Monograph Part II: </em>CLINICAL TRIALS)</strong>.</p><p>Nosocomial pneumonia due to methicillin-susceptible <em>Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae </em>or <em>Streptococcus pneumoniae. </em>Adjunctive therapy should be used as clinically indicated. Where <em>Pseudomonas aeruginosa </em>is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal &beta;-lactam is recommended.</p><p>&nbsp;</p><p><strong><em>PRINCEOXIN is not indicated for acute bronchitis.</em></strong></p><p><strong><em>PRINCEOXIN should not be prescribed to patients with acute bacterial exacerbations of simple/uncomplicated chronic obstructive pulmonary disease (ie. patients who have chronic obstructive pulmonary disease without underlying risk factors)</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong>Skin</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Skin</strong><strong> </strong><strong>Structure</strong></p><p>Uncomplicated skin and skin structure infections (mild to moderate) due to <em>Staphylococcus aureus </em>or <em>Streptococcus pyogenes.</em></p><p><em>&nbsp;</em></p><p>Complicated skin and skin structure infections (mild to moderate), excluding burns, due to <em>Enterococcus faecalis, </em>methicillin-sensitive <em>Staphylococcus aureus, Streptococcus pyogenes, Proteus mirabilis, </em>or <em>Streptococcus agalactiae.</em></p><p><em>&nbsp;</em></p><p><strong>Urinary</strong><strong> </strong><strong>Tract</strong></p><p>Complicated urinary tract infections (mild to moderate) due to <em>Enterococcus (Streptococcus) faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, </em>or <em>Pseudomonas aeruginosa </em><strong>(see DOSAGE AND ADMINISTRATION and <em>Product Monograph Part II: </em>CLINICAL TRIALS).</strong></p><p><strong>&nbsp;</strong></p><p>Uncomplicated urinary tract infections (mild to moderate) due to <em>Escherichia coli, Klebsiella pneumoniae </em>or <em>Staphylococcus saprophyticus.</em></p><p><em>&nbsp;</em></p><p>Acute pyelonephritis (mild to moderate) caused by <em>Escherichia coli </em><strong>(see DOSAGE AND ADMINISTRATION and <em>Product Monograph Part II: </em>CLINICAL TRIALS).</strong></p><p>Chronic bacterial prostatitis due to <em>Escherichia coli, Enterococcus faecalis, </em>or <em>Staphylococcus epidermidis.</em></p><p><em>&nbsp;</em></p><p>Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing the infection, and to determine their susceptibility to levofloxacin. Therapy with levofloxacin may be initiated before the results of these tests are known; once results become available, appropriate therapy should be continued.</p><p>&nbsp;</p><p><strong><em>In cases of uncomplicated acute bacterial cystitis, limit the use of PRINCEOXIN to circumstances where no other treatment options are available. A urine culture should be obtained prior to treatment to ensure levofloxacin susceptibility.</em></strong></p><p>&nbsp;</p><p>As with other drugs in this class, some strains of <em>Pseudomonas aeruginosa </em>may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy, will reveal not only the therapeutic effect of the antimicrobial agent, but also the possible emergence of bacterial resistance.</p><p>&nbsp;</p><p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of APO- LEVOFLOXACIN and other antibacterial drugs, PRINCEOXIN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p><p>&nbsp;</p><p><strong>Geriatric</strong><strong> </strong><strong>(&ge; 65 years of age):</strong></p><p>Drug absorption appears to be unaffected by age. Dose adjustment based on age alone is not necessary (see <strong>WARNINGS AND PRECAUTIONS, <u>Special Populations </u></strong>and <strong>ACTION AND CLINICAL PHARMACOLOGY, <u>Special Populations and Conditions</u></strong>).</p><p>&nbsp;</p><p><strong>Pediatric Use (&lt;18 years of age):</strong></p><p>Safety and effectiveness in children under 18 years of age have not been established (see&nbsp;<strong>WARNINGS<strong> </strong>AND</strong><strong> </strong><strong>PRECAUTIONS,</strong><strong> </strong><strong><u>Special Populations</u></strong>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Dosing</u></strong><strong><u> </u></strong><strong><u>Considerations</u></strong></p><p>The dosage of PRINCEOXIN tablets for patients with normal renal function (i.e., ClCr,&gt; 80 mL/min) is described in the following dosing chart. For patients with altered renal function (i.e., ClCr&nbsp;&le; 80 mL/min), see <u>Patients with Impaired Renal Function </u>subsection.</p><p>&nbsp;</p><p><strong><u>Recommended</u></strong><strong><u> </u></strong><strong><u>Dose</u></strong><strong><u> </u></strong><strong><u>and Dosage Adjustment</u></strong></p><p>Patients with Normal Renal Function</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Infection*</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>Freq.</strong></p></td><td style="vertical-align:top"><p><strong>Duration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Acute bacterial</p></td><td style="vertical-align:top"><p>500mg</p></td><td style="vertical-align:top"><p>q24h</p></td><td style="vertical-align:top"><p>7 days</p></td></tr><tr><td style="vertical-align:top"><p>Exacerbation of chronic Bronchitis</p></td><td style="vertical-align:top"><p>750mg</p></td><td style="vertical-align:top"><p>q24h</p></td><td style="vertical-align:top"><p>5 days</p></td></tr><tr><td style="vertical-align:top"><p>Comm.- Acquired Pneumonia</p></td><td style="vertical-align:top"><p>500mg</p></td><td style="vertical-align:top"><p>q24h</p></td><td style="vertical-align:top"><p>7-14 days (10-14 days for severe infections)</p></td></tr><tr><td style="vertical-align:top"><p>Sinusitis</p></td><td style="vertical-align:top"><p>750mg **</p><p>500mg</p><p>750mg ***</p></td><td style="vertical-align:top"><p>q24h</p><p>q24h</p><p>q24h</p></td><td style="vertical-align:top"><p>5 days</p><p>10-14 days</p><p>5 days</p></td></tr><tr><td style="vertical-align:top"><p>Nosocomial Pneumonia</p></td><td style="vertical-align:top"><p>750mg</p></td><td style="vertical-align:top"><p>q24h</p></td><td style="vertical-align:top"><p>7‐14 days</p></td></tr><tr><td style="vertical-align:top"><p>Uncomplicated SSSI</p></td><td style="vertical-align:top"><p>500mg</p></td><td style="vertical-align:top"><p>q24h</p></td><td style="vertical-align:top"><p>7‐14 days</p></td></tr><tr><td style="vertical-align:top"><p>Complicated SSSI</p></td><td style="vertical-align:top"><p>750mg</p></td><td style="vertical-align:top"><p>q24h</p></td><td style="vertical-align:top"><p>7‐14 days</p></td></tr><tr><td style="vertical-align:top"><p>Chronic Bacterial Prostatitis</p></td><td style="vertical-align:top"><p>500mg</p></td><td style="vertical-align:top"><p>q24h</p></td><td style="vertical-align:top"><p>28 days</p></td></tr><tr><td style="vertical-align:top"><p>Complicated UTI</p></td><td style="vertical-align:top"><p>250mg</p><p>750 mg****</p><p>250mg</p></td><td style="vertical-align:top"><p>q24h</p><p>q24h</p><p>q24h</p></td><td style="vertical-align:top"><p>10 days</p><p>5 days</p><p>10 days</p></td></tr><tr><td style="vertical-align:top"><p>Acute Pyelonephritis</p></td><td style="vertical-align:top"><p>250mg</p><p>750mg</p></td><td style="vertical-align:top"><p>q24h</p><p>q24h</p></td><td style="vertical-align:top"><p>10 days</p><p>5 days</p></td></tr><tr><td style="vertical-align:top"><p>Uncomplicated UTI</p></td><td style="vertical-align:top"><p>250mg</p></td><td style="vertical-align:top"><p>q24h</p></td><td style="vertical-align:top"><p>3 days</p></td></tr></tbody></table><p>&nbsp;</p><p>* DUE TO THE DESIGNATED PATHOGENS (see <strong>INDICATIONS</strong><strong> AND CLINICAL USE</strong>).</p><p>** Efficacy of this alternative regimen has only been documented for infections caused by penicillin-susceptible <em>Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, Chlamydia pneumoniae, </em>and <em>Legionella pneumophilia</em>.</p><p>*** The efficacy of a regimen of 750 mg daily for 5 days has been demonstrated to be non-inferior to a regimen of 500 mg daily for 10 days. The 750 mg daily 5-day regimen has not been compared to a regimen of 500 mg daily for 11-14 days.</p><p>****The efficacy of this alternative regimen has been documented for infections caused by Escherichia <em>coli, Klebsiella pneumoniae, and Proteus mirabilis. </em>Efficacy against infections caused by <em>Enterococcus faecalis, Enterobacter cloacae</em>, or <em>Pseudomonas aeruginosa </em>has not been demonstrated with this regimen.</p><p>&nbsp;</p><p><strong><u>Patients with Impaired Renal Function</u></strong></p><p>On the basis of the altered levofloxacin disposition pharmacokinetics in subjects with impaired renal function, dose adjustment is recommended for patients with impaired renal function as given below (see <strong>WARNINGS</strong><strong> AND PRECAUTIONS, <u>Renal; </u>ACTION AND CLINICAL</strong></p><p><strong>PHARMACOLOGY</strong>, <strong>Special Populations and Conditions, Renal Insufficiency and <em>Product Monograph Part II</em>: DETAILED PHARMACOLOGY, <u>Factors Influencing the</u> <u>Pharmacokinetics, </u></strong><u>Special</u><u> </u><u>Populations,</u><u> </u><strong>Renal Insufficiency</strong>).</p><p>&nbsp;</p><p>Dosing recommendations for renally impaired patients are based on data collected from a clinical safety and pharmacokinetic study in renally impaired patients treated with a single 500 mg oral dose of levofloxacin. There is no clinical experience available in this patient population for the 250 mg dose or 750 mg dose. Pharmacokinetic modelling was used to determine a recommended dosing regimen which would provide equivalent drug exposures for which clinical efficacy has been demonstrated. The potential effects of levofloxacin associated with possible increased serum/tissue levels in renal-impaired patients, such as effect on QTc interval, have not been studied.</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1032" style='width:469.5pt;
 height:.6pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9390,12">
 <v:group id="_x0000_s1033" style='position:absolute;left:6;top:6;width:9378;
  height:2' coordorigin="6,6" coordsize="9378,2">
  <v:shape id="_x0000_s1034" style='position:absolute;left:6;top:6;width:9378;
   height:2' coordorigin="6,6" coordsize="9378,0" path="m6,6r9378,e" filled="f"
   strokeweight=".58pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Renal Status</strong></p></td><td style="vertical-align:top"><p><strong>Initial</strong><strong> </strong><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>Subsequent Dose</strong></p></td></tr><tr><td style="vertical-align:top" colspan="3"><p><strong>Acute Sinusitis / Acute Bacterial Exacerbation of Chronic Bronchitis / Community Acquired Pneumonia / Uncomplicated SSSI / Chronic Bacterial Prostatitis</strong></p></td></tr><tr><td style="vertical-align:top"><p>ClCr&nbsp;from 50 to 80 mL/min</p></td><td style="vertical-align:top" colspan="2"><p>No dosage adjustment required</p></td></tr><tr><td style="vertical-align:top"><p>ClCr&nbsp;from 20 to 49 mL/min</p></td><td style="vertical-align:top"><p>500 mg</p></td><td style="vertical-align:top"><p>250 mg q24h</p></td></tr><tr><td style="vertical-align:top"><p>ClCr&nbsp;from 10 to 19 mL/min Hemodialysis</p></td><td style="vertical-align:top"><p>500 mg</p></td><td style="vertical-align:top"><p>250 mg q48h</p></td></tr><tr><td style="vertical-align:top"><p>Hemodialysis</p></td><td style="vertical-align:top"><p>500 mg</p></td><td style="vertical-align:top"><p>250 mg q48h</p></td></tr><tr><td style="vertical-align:top"><p>CAPD</p></td><td style="vertical-align:top"><p>500 mg</p></td><td style="vertical-align:top"><p>250 mg q48h</p></td></tr><tr><td style="vertical-align:top" colspan="3"><p><strong>Complicated UTI / Acute Pyelonephritis</strong></p></td></tr><tr><td style="vertical-align:top"><p>ClCr&nbsp;&ge; 20 mL/min</p></td><td style="vertical-align:top" colspan="2"><p>No dosage adjustment required</p></td></tr><tr><td style="vertical-align:top"><p>ClCr&nbsp;from 10 to 19 mL/min</p></td><td style="vertical-align:top"><p>250 mg</p></td><td style="vertical-align:top"><p>250 mg q48h</p></td></tr><tr><td style="vertical-align:top" colspan="3"><p><strong>Complicated SSSI / Nosocomial Pneumonia / Community Acquired Pneumonia / Acute Bacterial Exacerbation of Chronic Bronchitis/ Acute Sinusitis/Complicated UTI/Acute Pyelonephritis</strong></p></td></tr><tr><td style="vertical-align:top"><p>ClCr&nbsp;from 50 to 80 mL/min</p></td><td style="vertical-align:top" colspan="2"><p>No dosage adjustment required</p></td></tr><tr><td style="vertical-align:top"><p>ClCr&nbsp;from 20 to 49 mL/min</p></td><td style="vertical-align:top"><p>750 mg</p></td><td style="vertical-align:top"><p>750 mg q48h</p></td></tr><tr><td style="vertical-align:top"><p>ClCr&nbsp;from 10 to 19 mL/min Hemodialysis</p></td><td style="vertical-align:top"><p>750 mg</p><p>750 mg</p></td><td style="vertical-align:top"><p>500 mg q48h</p><p>500 mg q48h</p></td></tr><tr><td style="vertical-align:top"><p>Hemodialysis</p></td><td style="vertical-align:top"><p>750 mg</p></td><td style="vertical-align:top"><p>500 mg q48h</p></td></tr><tr><td style="vertical-align:top"><p>CAPD</p></td><td style="vertical-align:top"><p>750 mg</p></td><td style="vertical-align:top"><p>750 mg q48h</p></td></tr><tr><td style="vertical-align:top"><p><strong>Uncomplicated UTI</strong></p></td><td style="vertical-align:top" colspan="2"><p>No dosage adjustment required</p></td></tr></tbody></table><p>ClCr&nbsp;= &nbsp;creatinine clearances</p><p>CAPD = chronic ambulatory peritoneal dialysis</p><p>When only the serum creatinine is known, the following formula may be used to estimate creatinine clearance.</p><p><u>Men:</u>&nbsp;&nbsp;&nbsp; Creatinine Clearance (mL/min)</p><p>=&nbsp;&nbsp;<u>Weight (kq) x (140 - age) x 1.2</u></p><p>&nbsp; &nbsp; &nbsp;serum creatinine (mcmol/L)</p><p><u>Women:&nbsp;</u>0.85 x the value calculated for men.</p><p>&nbsp;</p><p>The serum creatinine should represent a steady state of renal function.</p><p>&nbsp;</p><p><strong><u>Missed Dose</u></strong></p><p>More than the prescribed dose of PRINCEOXIN should not be taken, even if a dose is missed.</p><p>&nbsp;</p><p><strong><u>Administration</u></strong></p><p><u>Tablets</u></p><p>PRINCEOXIN can be administered without regard to food. Doses should be administered at least 2 hours before or 2 hours after antacids containing calcium, magnesium, aluminum, sucralfate, metal cations such as iron, multi-vitamin preparations with zinc, or products containing any of these components.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PRINCEOXIN tablets are contraindicated in persons with a history of hypersensitivity to levofloxacin, quinolone antimicrobial agents or to any components of this product. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the Product Monograph.

Levofloxacin is also contraindicated in persons with a history of tendinitis or tendon rupture associated with the use of any member of the quinolone group of antimicrobial agents.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table style="width:689px" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td style="width:686px"><p><strong>Serious Warnings and Precautions</strong></p><p><strong><em>&nbsp;</em></strong></p><ul><li>Levofloxacin has been shown to prolong the QT interval of the electrocardiogram in some patients (see <strong>WARNINGS AND PRECAUTIONS</strong>, <strong><u>Cardiovascular</u></strong>).</li><li>Serious hypersensitivity and/or anaphylactic reactions have been reported in patients receiving quinolone therapy, including levofloxacin (see <strong>WARNINGS AND</strong></li><li><strong>PRECAUTIONS, <u>Immune</u></strong>).</li><li>Seizures may occur with quinolone therapy. PRINCEOXIN should be used with caution in patients with known or suspected CNS disorders which may predispose to seizures or lower the seizure threshold (see <strong>WARNINGS AND PRECAUTIONS, <u>Neurologic</u></strong>).</li><li>Fluoroquinolones, including levofloxacin, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid levofloxacin in patients with a known history of myasthenia gravis (see <strong>WARNINGS AND PRECAUTIONS</strong>, <strong>Musculoskeletal</strong>).</li><li>Fluoroquinolones, including Princeoxin, have been associated with disabling and potentially persistent adverse reactions which to date include, but are not limited to: tendonitis, tendon rupture, peripheral neuropathy and neuropsychiatric effects.</li></ul></td></tr></tbody></table><p><strong><u>Epidemiologic studies report an increased risk of aortic aneurysm and dissection after</u></strong><strong> </strong><strong><u>intake of fluoroquinolones, particularly in the older population.</u></strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and</u></strong><strong> </strong><strong><u>after consideration of other therapeutic options in patients with positive family history of</u></strong><strong> </strong><strong><u>aneurysm disease, or in patients diagnosed with pre-existing aortic aneurysm and/or</u></strong><strong> </strong><strong><u>aortic dissection, or in presence of other risk factors or conditions predisposing for aortic</u></strong><strong> </strong><strong><u>aneurysm and dissection (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome,</u></strong><strong> </strong><strong><u>Takayasu arteritis, giant cell arteritis, Behcet&#39;s disease, hypertension, known</u></strong><strong> </strong><strong><u>atherosclerosis).</u></strong></p><p><strong>&nbsp;</strong></p><p><strong><u>In case of sudden abdominal, chest or back pain, patients should</u></strong><strong><u> be advised to immediately</u></strong><strong> </strong><strong><u>consult a physician in an emergency department.</u></strong></p><p><strong>&nbsp;</strong></p><p><strong><u>General</u></strong></p><p>The administration of levofloxacin increased the incidence and severity of osteochondrosis in immature rats and dogs. Other quinolones also produce similar erosions in the weight-bearing joints and other signs of arthropathy in immature animals of various species. Consequently, levofloxacin should not be used in pre-pubertal patients (see <strong><em>Product Monograph Part II</em>: TOXICOLOGY</strong>).</p><p>&nbsp;</p><p>Although levofloxacin is soluble, adequate hydration of patients receiving levofloxacin should be maintained to prevent the formation of a highly concentrated urine. Crystalluria has been observed rarely in patients receiving other quinolones, when associated with high doses and an alkaline urine. Although crystalluria was not observed in clinical trials with levofloxacin, &nbsp;patients are encouraged to remain adequately hydrated.</p><p>&nbsp;</p><p>As with any antimicrobial drug, periodic assessment of organ system functions, including renal, hepatic, and hematopoietic, is advisable during prolonged therapy (see <strong>ADVERSE REACTIONS</strong>).</p><p>Use of levofloxacin with other drugs may lead to drug-drug interactions (see <strong>DRUG INTERACTIONS</strong>, <strong><u>Drug-Drug Interactions</u></strong>).</p><p>&nbsp;</p><p><strong>Sexually Transmitted Diseases</strong></p><p>Levofloxacin is not indicated for the treatment of syphilis or gonorrhea. Levofloxacin is not effective in the treatment of syphilis. Antimicrobial agents used in high doses for short periods of time to treat gonorrhea may mask or delay the symptoms of incubating syphilis. All patients with gonorrhea should have a serologic test for syphilis at the time of diagnosis. Patients treated with antimicrobial agents with limited or no activity against <em>Treponema pallidum </em>should have a follow- up serologic test for syphilis after 3 months.</p><p>&nbsp;</p><p><strong><u>Cardiovascular</u></strong><strong> QT Prolongation</strong></p><p>Some quinolones, including levofloxacin, have been associated with prolongation of the QT interval on the electrocardiogram and infrequent cases of arrhythmia. During post-marketing surveillance, very rare cases of torsades de pointes have been reported in patients taking levofloxacin. These reports generally involved patients with concurrent medical conditions or concomitant medications that may have been contributory. The risk of arrhythmias may be reduced by avoiding concurrent use with other drugs that prolong the QT interval including macrolide antibiotics, antipsychotics, tricyclic antidepressants, Class IA (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic agents, and cisapride. In addition, use of levofloxacin in the presence of risk factors for torsades de pointes such as hypokalemia, significant bradycardia, cardiomyopathy, patients with myocardial ischemia, and patients with congenital prolongation of the QT interval should be avoided (see <strong><em>Product&nbsp;</em></strong><strong><em>Monograph Part II: </em></strong><strong>DETAILED</strong><strong> </strong><strong>PHARMACOLOGY,</strong><strong> </strong><strong><u>Human</u></strong><strong><u> </u></strong><strong><u>Pharmacology,</u></strong><strong><u> </u></strong><strong><u>Studies</u></strong><strong> </strong><strong><u>Measuring Effects on QT and Corrected QT (QTc) Intervals</u></strong>).</p><p>&nbsp;</p><p><strong><u>Endocrine and Metabolism</u></strong><strong> Disturbances of Blood Glucose</strong></p><p>Disturbances of blood glucose, including symptomatic hyper- and hypoglycemia, have been reported with the use of quinolones, including levofloxacin. In patients treated with levofloxacin, some of these cases were serious. Blood glucose disturbances were usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide/glibenclamide) and/or with insulin. In these patients, careful monitoring of blood glucose is recommended. If a hypoglycemic reaction occurs in a patient being treated with levofloxacin, discontinue levofloxacin immediately and initiate appropriate therapy. Serious hypoglycemia and hyperglycemia have also occurred in patients without a history of diabetes (see <strong>ADVERSE REACTIONS and DRUG INTERACTIONS, <u>Drug-Drug Interactions, </u>Antidiabetic Agents</strong>).</p><p>&nbsp;</p><p>Hypoglycemic coma has been observed in diabetic patients with the use of levofloxacin. Fatal outcomes have been reported. All cases of hypoglycemic coma had multiple confounding factors; a temporal relationship with the use of levofloxacin was identified (onset of altered consciousness occurred within 3 days in most cases). Caution should be exercised when using</p><p>&nbsp;</p><p>levofloxacin in diabetic patients taking concomitant treatment with an oral hypoglycemic agent and/or insulin, especially those who are elderly or who have renal impairment (see <strong>WARNINGS AND PRECAUTIONS, Renal and DRUG INTERACTIONS, <u>Drug-Drug Interactions,</u> Antidiabetic Agents</strong>).</p><p>&nbsp;</p><p><strong><u>Gastrointestinal</u></strong></p><p><strong>Clostridium</strong><strong> </strong><strong>difficile-associated</strong><strong> </strong><strong>disease</strong></p><p>Clostridium difficile-associated disease (CDAD) has been reported with use of many antibacterial agents, including levofloxacin. CDAD may range in severity from mild diarrhea to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea or symptoms of colitis, pseudomembranous colitis, toxic megacolon, or perforation of the colon subsequent to the administration of any antibacterial agent. CDAD has been reported to occur over 2 months after the administration of antibacterial agents.</p><p>&nbsp;</p><p>Treatment with antibacterial agents may alter the normal flora of the colon and may permit overgrowth of <em>Clostridium difficile</em>. <em>C. difficile </em>produces toxins A and B, which contribute to the development of CDAD. CDAD may cause significant morbidity and mortality. CDAD can be refractory to antimicrobial therapy.</p><p>&nbsp;</p><p>If the diagnosis of CDAD is suspected or confirmed, appropriate therapeutic measures should be initiated. Mild cases of CDAD usually respond to discontinuation of antibacterial agents not directed against <em>Clostridium difficile</em>. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial agent clinically effective against <em>Clostridium difficile. </em>Surgical evaluation should be instituted as clinically indicated since surgical intervention may be required in certain severe cases (see <strong>ADVERSE REACTIONS</strong>).</p><p>&nbsp;</p><p><strong><u>Hepatic</u></strong></p><p>Very rare post-marketing reports of severe hepatotoxicity (including acute hepatitis and fatal events) have been received for patients treated with levofloxacin. No evidence of serious drug- associated hepatotoxicity was detected in clinical trials of over 7,000 patients. Severe hepatotoxicity generally occurred within 14 days of initiation of therapy and most cases occurred within 6 days. Most cases of severe hepatotoxicity were not associated with hypersensitivity. The majority of fatal hepatotoxicity reports occurred in patients 65 years of age or older and most were not associated with hypersensitivity. Levofloxacin should be discontinued immediately if the patient develops signs and symptoms of hepatitis (see <strong>ADVERSE REACTIONS, <u>Post- Market</u> <u>Adverse Drug Reactions</u></strong>).</p><p>&nbsp;</p><p><strong><u>Immune</u></strong><strong><u> </u></strong><strong>Hypersensitivity</strong></p><p>Serious and occasionally fatal hypersensitivity and/or anaphylactic reactions have been reported in patients receiving therapy with quinolones, including levofloxacin. These reactions often occur following the first dose. Some reactions have been accompanied by cardiovascular collapse, hypotension/shock, seizure, loss of consciousness, tingling, angioedema (including tongue, laryngeal, throat or facial edema/swelling), airway obstruction (including bronchospasm, shortness of breath, and acute respiratory distress), dyspnea, urticaria, itching, and other serious skin reactions. Levofloxacin should be discontinued immediately at the first appearance of a skin rash or any other sign of hypersensitivity. Serious acute hypersensitivity reactions may require</p><p>&nbsp;</p><p>treatment with epinephrine and other resuscitative measures, including oxygen, intravenous fluids, antihistamines, corticosteroids, pressor amines and airway management, as clinically indicated (see <strong>ADVERSE REACTIONS)</strong>.</p><p>&nbsp;</p><p>Serious and sometimes fatal events, some due to hypersensitivity and some due to uncertain etiology, have rarely been reported in patients receiving therapy with quinolones, including levofloxacin. These events may be severe and generally occur following the administration of multiple doses. Clinical manifestations may include one or more of the following: fever; rash or severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome); vasculitis; arthralgia; myalgia; serum sickness; allergic pneumonitis; interstitial nephritis; acute renal insufficiency or failure; hepatitis, including acute hepatitis; jaundice; acute hepatic necrosis or failure; anemia, including hemolytic and aplastic; thrombocytopenia, including thrombotic thrombocytopenic purpura; leukopenia; agranulocytosis; pancytopenia; and/or other hematologic abnormalities. The administration of levofloxacin should be discontinued immediately, at the first appearance of a skin rash or any other sign of hypersensitivity, and supportive measures instituted (see <strong>ADVERSE REACTIONS</strong>).</p><p>&nbsp;</p><p><strong><u>Musculoskeletal</u></strong><strong> </strong><strong>Tendinitis</strong></p><p><strong>Rupture</strong><strong> </strong><strong>of </strong><strong>the</strong><strong> shoulder, hand and Achilles tendons that required surgical repair or resulted in prolonged disability have been reported in patients receiving quinolones, including levofloxacin</strong>. Levofloxacin should be discontinued if the patient experiences pain, inflammation or rupture of a tendon. Patients should rest and refrain from exercise until the diagnosis of tendinitis or tendon rupture has been confidently excluded. The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. Factors, in addition to age and corticosteroid use, that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis. Tendinitis and tendon rupture have also occurred in patients taking fluoroquinolones who do not have the above risk factors. Tendon rupture can occur during or after completion of therapy; cases occurring up to several months after completion of therapy have been reported.</p><p>Levofloxacin should be discontinued if the patient experiences pain, swelling, inflammation or rupture of a tendon. Patients should be advised to rest at the first sign of tendinitis or tendon rupture, and to contact their healthcare provider regarding changing to a non-quinolone antimicrobial drug (see <strong>ADVERSE REACTIONS</strong>).</p><p>&nbsp;</p><p>Levofloxacin should not be used in patients with a history of tendon disease/disorder related to previous quinolone treatment (see <strong>CONTRAINDICATIONS</strong>).</p><p>&nbsp;</p><p><strong>Myasthenia</strong><strong> </strong><strong>Gravis</strong></p><p>Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis. Post-marketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolone use (including levofloxacin) in persons with myasthenia gravis. Avoid levofloxacin in patients with a known history of myasthenia gravis (see <strong>ADVERSE REACTIONS, <u>Post-Market Adverse Drug Reactions</u></strong>) <strong>&nbsp;<u>Neurologic</u></strong></p><p>&nbsp;</p><p><strong><u>CNS</u></strong><strong><u> </u></strong><strong><u>and</u></strong><strong><u> </u></strong><strong><u>Psychiatric</u></strong><strong><u> </u></strong><strong><u>Effects</u></strong></p><p>Convulsions, toxic psychoses and increased intracranial pressure (including pseudotumor cerebri) have been reported in patients receiving quinolones, including levofloxacin. Quinolones including levofloxacin, may also cause central nervous system stimulation which may lead to tremors, restlessness, anxiety, lightheadedness, dizziness, confusion and hallucinations, paranoia, depression, nightmares, insomnia and, rarely, suicidal thoughts or acts. These reactions may&nbsp; occur following the first dose. If these reactions occur in patients receiving levofloxacin, the drug should be discontinued and appropriate measures instituted. As with all quinolones, levofloxacin should be used with caution in patients with a known or suspected CNS disorder that may predispose to seizures or lower the seizure threshold (e.g., severe cerebral arteriosclerosis, epilepsy), or in the presence of other risk factors that may predispose to seizures or lower the seizure threshold (e.g., alcohol abuse, certain drug therapies such as NSAIDs and theophylline, renal dysfunction).</p><p>Levofloxacin should be used with caution in patients with unstable psychiatric illness (see <strong>DRUG INTERACTIONS </strong>and <strong>ADVERSE REACTIONS</strong>).</p><p>&nbsp;</p><p><strong>Peripheral Neuropathy</strong></p><p>Rare cases of sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoesthesias, dysesthesias and weakness have been reported in patients receiving quinolones, including levofloxacin. Symptoms may occur soon after initiation of treatment and may be irreversible. Levofloxacin should be discontinued immediately if the patient experiences symptoms of neuropathy including pain, burning, tingling, numbness, and/or weakness or other alterations of sensation including light touch, pain, temperature, position sense, and vibratory sensation in order to prevent the development of an irreversible condition.</p><p>&nbsp;</p><p><u><strong>Ophthalmologic</strong><strong> </strong><strong>Vision Disorders</strong></u></p><p>Consult an eye specialist if vision disorder occurs in association with the use of APO-Levofloxacin.</p><p>&nbsp;</p><p><strong><u>Renal</u></strong></p><p>Safety and efficacy of levofloxacin in patients with impaired renal function (creatinine clearance &le; 80 mL/min) have not been studied. Since levofloxacin is known to be substantially excreted by the kidney, the risk of toxic reactions to this drug may be greater in patients with impaired renal function. The potential effects of levofloxacin associated with possible increased serum/tissue levels in renal impaired patients, such as effect on QTc interval, have not been studied.</p><p>Adjustment of the dosage regimen may be necessary to avoid the accumulation of levofloxacin due to decreased clearance. Careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy, since elimination of levofloxacin may be reduced.</p><p>Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function. Administer levofloxacin with caution in the presence of renal insufficiency <strong>(see <u>DOSAGE AND ADMINISTRATION,</u> <u>Recommended Dose and Dosage Adjustment</u></strong><u>, Patients with Impaired </u><u>Renal Function </u>and <strong><em>Product Monograph Part II</em></strong><em>: </em><strong>DETAILED PHARMACOLOGY</strong>, <strong><u>Factors Influencing the</u> <u>Pharmacokinetics</u></strong>, <u>Special Populations, </u><strong>Renal Insufficiency<em>).</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><u><strong>Skin</strong><strong> </strong><strong>Phototoxicity</strong></u></p><p>Moderate to severe phototoxicity reactions have been observed in patients exposed to direct sunlight or ultraviolet (UV) light while receiving drugs in this class. Excessive exposure to sunlight or UV light should be avoided. However, in clinical trials with levofloxacin, phototoxicity has been observed in less than 0.1% of patients. Therapy should be discontinued if phototoxicity (e.g., skin eruption) occurs.</p><p>&nbsp;</p><p><strong>Susceptibility/Resistance</strong></p><p><strong><u>Development of Drug Resistant Bacteria</u></strong></p><p><strong>Prescribing</strong><strong> </strong>PRINCEOXIN <strong>in</strong><strong> </strong><strong>the absence of</strong><strong> </strong><strong>a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and risks the development of drug- resistant bacteria.</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Special Populations</u></strong></p><p>The safety and efficacy of levofloxacin tablets in children, adolescents (under the age of 18 years), pregnant women and nursing mothers have not been established.</p><p>&nbsp;</p><p><strong>Pediatrics (&lt;18 years of age): </strong>Levofloxacin is not indicated for the treatment of patients younger than 18 years of age. Quinolones, including levofloxacin, cause arthropathy in juvenile animals of several species (see <strong><em>Product Monograph Part II</em>: TOXICOLOGY</strong>). The incidence of protocol-defined musculoskeletal disorders in a prospective long-term surveillance study was higher in children treated for approximately 10 days with levofloxacin than in children treated with non-fluoroquinolone antibiotics for approximately 10 days (see <strong>ADVERSE REACTIONS</strong>).</p><p>&nbsp;</p><p><strong>Geriatrics</strong><strong> </strong><strong>(&ge;65</strong><strong> </strong><strong>years of age)</strong>: The pharmacokinetic properties of levofloxacin in younger adults and elderly adults do not differ significantly when creatinine clearance is taken into consideration. However, since the drug is known to be substantially excreted by the kidney, the risk of toxic reactions to this drug may be greater in patients with impaired renal function.</p><p>Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection. It may also be useful to monitor renal function.</p><p>&nbsp;</p><p>Elderly patients may be more susceptible to drug-associated effects on the QT interval (see&nbsp;<strong>WARNINGS<strong> </strong>AND</strong><strong> </strong><strong>PRECAUTIONS,</strong><strong> </strong><strong><u>Cardiovascular</u></strong>).</p><p>&nbsp;</p><p>Geriatric patients are at increased risk for developing severe tendon disorders including tendon rupture when being treated with a fluoroquinolone such as levofloxacin. This risk is further increased in patients receiving concomitant corticosteroid therapy (see <strong>WARNINGS AND PRECAUTIONS</strong>, <strong><u>Musculoskeletal</u></strong>).</p><p>&nbsp;</p><p>Severe and sometimes fatal cases of hepatotoxicity have been reported post‐marketing in association with levofloxacin. The majority of fatal hepatotoxicity reports occurred in patients 65 years of age or older and most were not associated with hypersensitivity (see <strong>WARNINGS AND PRECAUTIONS</strong>, <strong><u>Hepatic</u></strong>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Overview</u></strong></p><p>Levofloxacin undergoes limited metabolism in humans and is primarily excreted as unchanged drug in the urine. The P450 system is not involved in the levofloxacin metabolism, and is not affected by levofloxacin. Levofloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these enzymes. Disturbances of blood glucose have been reported in patients treated concomitantly with levofloxacin and an antidiabetic agent. Therefore, careful monitoring of blood glucose is recommended when these agents, including levofloxacin, are coadministered. As with all other quinolones, iron and antacids significantly reduced bioavailability of levofloxacin.</p><p>&nbsp;</p><p><strong><u>Drug-Drug Interactions</u></strong></p><p><strong>Table 1.4: Established or Potential Drug-Drug Interactions</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:102px"><p><strong>Proper</strong><strong> </strong><strong>name</strong></p></td><td style="vertical-align:top; width:46px"><p><strong>Ref</strong></p></td><td style="vertical-align:top; width:449px"><p><strong>Effect</strong></p></td><td style="vertical-align:top; width:201px"><p><strong>Clinical</strong><strong> </strong><strong>comment</strong></p></td></tr><tr><td style="vertical-align:top; width:102px"><p><u>Antacids, </u><u>Sucralfate,</u> <u>Metal </u><u>Cations,</u><u> </u><u>Multi-</u> <u>Vitamins</u></p></td><td style="vertical-align:top; width:46px"><p>T</p></td><td style="vertical-align:top; width:449px"><p><strong>Tablets</strong>: Due to the chelation of levofloxacin by multivalent cations, concurrent administration of levofloxacin tablets with antacids containing calcium, magnesium, or aluminum, as well as sucralfate, metal cations such as iron, multi- vitamin preparations with zinc, or any products containing any of these components may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired.</p></td><td style="vertical-align:top; width:201px"><p>These agents should be taken at least 2 hours before or 2 hours after levofloxacin tablet administration.</p></td></tr><tr><td style="vertical-align:top; width:102px"><p><u>Antidiabetic</u><u> Agents</u></p></td><td style="vertical-align:top; width:46px"><p>C</p></td><td style="vertical-align:top; width:449px"><p>Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with levofloxacin and an antidiabetic agent. Some of these cases were serious including hypoglycemic coma.</p></td><td style="vertical-align:top; width:201px"><p>Careful monitoring of blood glucose is recommended when</p><p>these agents, including levofloxacin, are co-administered.</p></td></tr><tr><td style="vertical-align:top; width:102px"><p><u>Cyclosporine</u></p></td><td style="vertical-align:top; width:46px"><p>CT</p></td><td style="vertical-align:top; width:449px"><p>No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for cyclosporine was detected in a clinical study involving healthy volunteers. However, elevated serum levels of</p><p>cyclosporine have been reported in the patient population when co- administered with some other quinolones. Levofloxacin Cmax&nbsp;and ke were slightly lower, while Tmax&nbsp;and t&frac12;&nbsp;were slightly longer in the presence of cyclosporine, than those observed in other studies without concomitant medication. &nbsp;The differences, however, are not considered to be clinically significant.</p></td><td style="vertical-align:top; width:201px"><p>No dosage adjustment is required for levofloxacin or cyclosporine when administered concomitantly.</p></td></tr><tr><td style="vertical-align:top; width:102px"><p><u>Digoxin</u></p></td><td style="vertical-align:top; width:46px"><p>CT</p></td><td style="vertical-align:top; width:449px"><p>No significant effect of levofloxacin on the peak plasma concentrations, AUC, and, other disposition parameters for digoxin was detected in a clinical study involving healthy volunteers. Levofloxacin absorption and disposition kinetics were similar in the presence or absence of digoxin.</p></td><td style="vertical-align:top; width:201px"><p>No dosage adjustment for levofloxacin or digoxin is required when administered concomitantly. Digoxin levels should be closely monitored in patients receiving concomitant therapy with digoxin.</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:102px"><p>Non-Steroidal Anti- Inflammatory Drugs (NSAIDs)</p></td><td style="vertical-align:top; width:39px"><p>T</p></td><td style="vertical-align:top; width:453px"><p>Although not observed with levofloxacin in clinical trials, some quinolones have been reported to have proconvulsant activity that is exacerbated with concomitant use of NSAIDs.</p></td><td style="vertical-align:top; width:202px"><p>The concomitant administration of a non-steroidal anti-inflammatory drug with a quinolone, including levofloxacin, may increase the risk</p><p>of CNS stimulation and convulsive seizures (see <strong>WARNINGS AND PRECAUTIONS; <u>Neurologic </u></strong>and <strong><em>Product Monograph Part II, </em>DETAILED PHARMACOLOGY,</strong></p><p><strong><u>Animal</u></strong><strong><u> </u></strong><strong><u>Pharmacology</u></strong>).</p></td></tr><tr><td style="vertical-align:top; width:102px"><p>Probenecid and Cimetidine</p></td><td style="vertical-align:top; width:39px"><p>CT</p></td><td style="vertical-align:top; width:453px"><p>No significant effect of probenecid or cimetidine on the rate and extent of levofloxacin absorption was observed in a clinical study involving healthy volunteers. The</p><p>AUC and t&frac12;&nbsp;of levofloxacin were 27- 38% and 30% higher, respectively, while CL/F and Clr&nbsp;were 21-35% lower during concomitant treatment with probenecid or cimetidine compared to levofloxacin alone.</p></td><td style="vertical-align:top; width:202px"><p>No dosage adjustment for levofloxacin is required when administered concomitantly with probenecid or cimetidine except dosage adjustment for levofloxacin may be required based on the renal function of the patient.</p></td></tr><tr><td style="vertical-align:top; width:102px"><p>Theophylline</p></td><td style="vertical-align:top; width:39px"><p>CT/T</p></td><td style="vertical-align:top; width:453px"><p>No significant effect of levofloxacin on the plasma concentrations, AUC, and other disposition parameters for theophylline was detected in a clinical study involving 14 healthy volunteers. Similarly, no apparent effect of theophylline on levofloxacin absorption and disposition was observed. However, concomitant administration of other quinolones with theophylline has</p></td><td style="vertical-align:top; width:202px"><p>Theophylline levels should be closely monitored, and theophylline dosage adjustments made if appropriate, when levofloxacin is co- administered. Adverse reactions, including seizures, may occur with or without an elevation in serum theophylline level (see WARNINGS AND PRECAUTIONS,</p></td></tr><tr><td style="vertical-align:top; width:102px"><p>Warfarin</p></td><td style="vertical-align:top; width:39px"><p>T</p></td><td style="vertical-align:top; width:453px"><p>Certain quinolones, including levofloxacin, may enhance the effects of oral anticoagulant warfarin or its derivatives.</p></td><td style="vertical-align:top; width:202px"><p>When these products are administered concomitantly, prothrombin time, International Normalized Ratio (INR), or other suitable coagulation tests should be monitored closely, especially in elderly patients.</p></td></tr><tr><td style="vertical-align:top; width:102px"><p>Zidovudine</p></td><td style="vertical-align:top; width:39px"><p>CT</p></td><td style="vertical-align:top; width:453px"><p>Levofloxacin absorption and disposition in HIV-infected subjects, with or without concomitant zidovudine treatment, were similar. The effect of levofloxacin on zidovudine pharmacokinetics has not been studied.</p></td><td style="vertical-align:top; width:202px"><p>No dosage adjustment for levofloxacin appears to be required when co-administered with zidovudine.</p></td></tr></tbody></table><p>Legend: C = Case Study; CT = Clinical Trial; T = Theoretical</p><p>&nbsp;</p><p><strong><u>Drug-Food Interactions</u></strong></p><p>PRINCEOXIN may be taken with or without food.</p><p>&nbsp;</p><p><strong><u>Drug-Herb Interactions</u></strong></p><p>Interactions with herbal products have not been established.</p><p>&nbsp;</p><p><strong><u>Drug-Laboratory Interactions</u></strong></p><p>Some quinolones, including levofloxacin, may produce false-positive urine screening results for opiates using commercially available immunoassay kits. Confirmation of positive opiate screens by more specific methods may be necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnant Women: </strong>There are no adequate and well-controlled studies in pregnant women. Levofloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus (see <strong><em>Product Monograph Part II</em>: TOXICOLOGY</strong>).</p><p>&nbsp;</p><p><strong>Nursing Women: </strong>Levofloxacin has not been measured in human milk. Based upon data from ofloxacin, it can be presumed that levofloxacin can be excreted in human milk. Because of the potential for serious adverse reactions from levofloxacin in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother (see <strong><em>Product Monograph Part II</em>: TOXICOLOGY</strong>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Neurologic adverse effects such as dizziness and lightheadedness may occur. Therefore, patients should know how they react to levofloxacin before operating an automobile or machinery or engaging in other activities requiring mental alertness and coordination.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Adverse Drug Reaction Overview</u></strong></p><p>In North American Phase III clinical trials involving 7537 subjects, the incidence of treatment- emergent adverse events in patients treated with levofloxacin tablets and injection was comparable to comparators. The majority of adverse events were considered to be mild to moderate, with 5.6% of patients considered to have severe adverse events. Among patients receiving multiple-dose therapy, 4.2% discontinued therapy with levofloxacin due to adverse experiences. The incidence of drug-related adverse reactions was 6.7%.</p><p>In clinical trials, the most frequently reported adverse drug reactions occurring in &gt; 3% of the study population were nausea, headache, diarrhea, insomnia, dizziness and constipation.</p><p>Serious and otherwise important adverse drug reactions are discussed in greater detail in other sections (see <strong>WARNINGS AND PRECAUTIONS</strong>).</p><p>&nbsp;</p><p><strong><u>Clinical Trial Adverse Drug Reactions</u></strong></p><p><em>Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.</em></p><p><em>&nbsp;</em></p><p>The data described below reflect exposure to levofloxacin in 7537 patients in 29 pooled Phase III clinical trials. The population studied had a mean age of 49.6 years (74.2% of the population was &lt; 65 years), 50.1% were male, 71.0% were Caucasian, 18.8% were Black. Patients were treated with levofloxacin for a wide variety of infectious diseases (see <strong>INDICATIONS AND CLINICAL USE</strong>). Treatment duration was usually 3 to 14 days, the mean number of days on therapy was 9.6 days and the mean number of doses was 10.2. Patients received levofloxacin doses of 750 mg once daily, 250 mg once daily, or 500 mg once or twice daily. The overall incidence, type and distribution of adverse reactions were similar in patients receiving levofloxacin doses of 750 mg once daily, 250 mg once daily, and 500 mg once or twice daily.</p><p>Adverse reactions (characterized as likely related to drug-therapy) occurring in &ge;1% of levofloxacin-treated patients are shown in Table 1.1 below.</p><p>&nbsp;</p><p><strong>Table 1.1: Common (&ge;1%) Adverse Reactions Reported in Clinical Trials with Levofloxacin</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System/Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>% (N=7537)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections</strong><strong> </strong><strong>and Infestations</strong></p></td><td style="vertical-align:top"><p>moniliasis</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric</strong><strong> Disorders</strong></p></td><td style="vertical-align:top"><p>insomnia</p></td><td style="vertical-align:top"><p>4a</p></td></tr><tr><td style="vertical-align:top" rowspan="2"><p><strong>Nervous System Disorders</strong></p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>dizziness</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory,</strong><strong> </strong><strong>Thoracic</strong><strong> and Mediastinal Disorders</strong></p></td><td style="vertical-align:top"><p>dyspnea</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top" rowspan="6"><p><strong>Gastrointestinal</strong><strong> </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>nausea</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>diarrhea</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>constipation</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>abdominal pain</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>vomiting</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>dyspepsia</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and</strong><strong> </strong><strong>Subcutaneous</strong><strong> Tissue</strong></p></td><td style="vertical-align:top"><p>rash</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>pruritus</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive</strong><strong> </strong><strong>System</strong><strong> </strong><strong>and Breast Disorders</strong></p></td><td style="vertical-align:top"><p>vaginitis</p></td><td style="vertical-align:top"><p>1b</p></td></tr><tr><td style="vertical-align:top"><p><strong>General</strong><strong> </strong><strong>Disorders</strong><strong> </strong><strong>and</strong></p></td><td style="vertical-align:top"><p>edema</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top" rowspan="2"><p><strong>Administration Site Conditions</strong></p></td><td style="vertical-align:top"><p>injection site reaction</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>chest pain</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top" colspan="3"><p>a N = 7274</p><p>b N = 3758 (women)</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><u>Less</u></strong><strong><u> </u></strong><strong><u>Common</u></strong><strong><u> </u></strong><strong><u>Clinical</u></strong><strong><u> </u></strong><strong><u>Trial</u></strong><strong><u> </u></strong><strong><u>Adverse</u></strong><strong><u> </u></strong><strong><u>Drug</u></strong><strong><u> </u></strong><strong><u>Reactions</u></strong><strong><u> </u></strong><strong><u>(&lt;1%)</u></strong></p><p>Less common adverse reactions occurring in 0.1 to &lt;1% of levofloxacin-treated patients are shown in Table 1.2 below.</p><p>&nbsp;</p><p><strong>Table 1.2: Less Common (0.1 to ˂1%) Adverse Reactions Reported in Clinical Trials with Levofloxacin</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System/Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood</strong><strong> and Lymphatic System Disorders</strong></p></td><td style="vertical-align:top"><p>anemia, thrombocytopenia, granulocytopenia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac</strong><strong> </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>cardiac arrest, palpitation, ventricular tachycardia, ventricular arrhythmia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal</strong><strong> </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>gastritis, stomatitis, pancreatitis, esophagitis, gastroenteritis, glossitis, pseudomembranous/ <em>C.difficile </em>colitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary</strong><strong> </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>abnormal hepatic function, increased hepatic enzymes, increased alkaline phosphatase</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune</strong><strong> System</strong><strong> Disorders</strong></p></td><td style="vertical-align:top"><p>allergic reaction</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections</strong><strong> </strong><strong>and Infestations</strong></p></td><td style="vertical-align:top"><p>genital moniliasis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and Nutrition</strong><strong> </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>hyperglycemia, hypoglycemia, hyperkalemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Connective</strong><strong> </strong><strong>Tissue</strong><strong> Disorders</strong></p></td><td style="vertical-align:top"><p>tendinitis, arthralgia, myalgia, skeletal pain</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous System Disorders</strong></p></td><td style="vertical-align:top"><p>tremor, convulsions, paresthesia, vertigo, hypertonia, hyperkinesias, abnormal gait, somnolencea, syncope</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric</strong><strong> Disorders</strong></p></td><td style="vertical-align:top"><p>anxiety, agitation, confusion, depression, hallucination, nightmarea, sleep disordera, anorexia, abnormal dreaminga</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and</strong><strong> Urinary </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>abnormal renal function, acute renal failure</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory,</strong><strong> </strong><strong>Thoracic</strong><strong> and Mediastinal Disorders</strong></p></td><td style="vertical-align:top"><p>epistaxis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td style="vertical-align:top"><p>urticaria</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular</strong><strong> </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>Phlebitis</p></td></tr></tbody></table><p>a N = 7274</p><p>Rare (&lt;0.1%) adverse reactions from Phase III studies include dyspnea and rash maculopapular.</p><p>&nbsp;</p><p>In clinical trials using multiple-dose therapy, ophthalmologic abnormalities, including cataracts and multiple punctate lenticular opacities, have been noted in patients undergoing treatment with other quinolones. The relationship of the drugs to these events is not presently established.</p><p>&nbsp;</p><p>Crystalluria and cylindruria have been reported with other quinolones.</p><p>&nbsp;</p><p><strong><u>Abnormal Hematologic and Clinical Chemistry Findings</u></strong></p><p>Laboratory abnormalities seen in &gt; 2% of patients receiving multiple doses of levofloxacin: decreased glucose 2.1%</p><p>It is not known whether this abnormality was caused by the drug or the underlying condition being treated.</p><p>&nbsp;</p><p><strong><u>Pediatric Data</u></strong></p><p>In a group of 1534 pediatric patients (6 months to 16 years of age) treated with levofloxacin for respiratory infections, children 6 months to 5 years of age received 10 mg/kg of levofloxacin twice a day for approximately 10 days and children greater than 5 years of age received 10 mg/kg to a maximum of 500 mg of levofloxacin once a day for approximately 10 days. The adverse reaction profile was similar to that reported in adult patients. Vomiting and diarrhea were reported more frequently in children than reported in adults. However, the frequency of vomiting and diarrhea was similar in levofloxacin-treated and non-fluoroquinolone antibiotic comparator-treated children.</p><p>&nbsp;</p><p>A subset of 1340 of these children treated with levofloxacin for approximately 10 days was enrolled in a prospective, long-term, surveillance study to assess the incidence of protocol- defined musculoskeletal disorders (arthralgia, arthritis, tendonopathy, gait abnormality) during 60 days and 1 year following the first dose of levofloxacin.</p><p>&nbsp;</p><p>During the 60-day period following the first dose, the incidence of protocol-defined musculoskeletal disorders was greater in levofloxacin-treated children than in non- fluoroquinolone antibiotic comparator-treated children (2.1% vs. 0.9%, respectively [p=0.038]). In 22/28 (78%) of these children, reported disorders were characterized as arthralgia. A similar observation was made during the one-year period, with a greater incidence of protocol-defined musculoskeletal disorders in levofloxacin-treated children than in non-fluoroquinolone antibiotic comparator-treated children (3.4% vs. 1.8%, respectively [p=0.025]). The majority of these disorders occurring in children treated with levofloxacin were mild and resolved within 7 days. Disorders were moderate in 8 children and mild in 35 (76%) children.</p><p>&nbsp;</p><p><strong><u>Post-market</u></strong><strong><u> </u></strong><strong><u>Adverse</u></strong><strong><u> </u></strong><strong><u>Drug Reactions</u></strong></p><p><strong>&nbsp;</strong></p><p>Table 1.3 lists adverse reactions that have been identified during post-approval use of levofloxacin. Because these reactions are reported voluntarily from a population of uncertain size, reliably estimating their frequency or establishing a causal relationship to drug exposure is not always possible.</p><p>&nbsp;</p><p><strong>Table 1.3: Post-marketing Reports of Adverse Drug Reactions</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System</strong><strong> </strong><strong>Organ </strong><strong>Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood</strong><strong> and Lymphatic System Disorders</strong></p></td><td style="vertical-align:top"><p>pancytopenia, aplastic anemia, leucopenia, hemolytic anemia, eosinophilia, thrombocytopenia including thrombotic thrombocytopenic purpura, agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac</strong><strong> </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>isolated reports of torsades de pointes, electrocardiogram QT prolonged, tachycardia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>uveitis, vision disturbance (including diplopia), visual acuity reduced, vision blurred, scotoma</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear</strong><strong> </strong><strong>and</strong><strong> Labyrinth Disorders</strong></p></td><td style="vertical-align:top"><p>hypoacusis, tinnitus</p></td></tr><tr><td style="vertical-align:top"><p><strong>General</strong><strong> </strong><strong>Disorders</strong><strong> </strong><strong>and </strong><strong>Administration</strong><strong> </strong><strong>Site</strong><strong> Conditions</strong></p></td><td style="vertical-align:top"><p>multi-organ failure, pyrexia, rash</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary</strong><strong> </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>hepatic failure (including fatal cases), hepatitis, jaundice, hepatic necrosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune</strong><strong> System</strong><strong> Disorders</strong></p></td><td style="vertical-align:top"><p>hypersensitivity reactions, sometimes fatal including: anaphylactic/anaphylactoid reactions, anaphylactic shock, angioneurotic edema, serum sickness</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>prothrombin time prolonged, international normalized ratio (INR) prolonged, muscle enzymes increased (CPK)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Connective</strong><strong> </strong><strong>Tissue</strong><strong> </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>tendon rupture, muscle injury (including rupture), rhabdomyolysis, myositis, myalgia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous System Disorders</strong></p></td><td style="vertical-align:top"><p>anosmia, ageusia, parosmia, dysgeusia, peripheral neuropathy (may be irreversible), isolated reports of encephalopathy, abnormal EEG, dysphonia exacerbation of myasthenia gravis, amnesia, pseudotumor cerebri</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric</strong><strong> Disorders</strong></p></td><td style="vertical-align:top"><p>psychosis, paranoia, isolated reports of suicide attempt and suicidal ideation</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and</strong><strong> Urinary </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>interstitial nephritis, nephrosis, glomerulonephritis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory,</strong><strong> </strong><strong>Thoracic</strong><strong> and Mediastinal Disorders</strong></p></td><td style="vertical-align:top"><p>isolated reports of allergic pneumonitis, interstitial pneumonia, laryngeal edema, apnea</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and</strong><strong> </strong><strong>Subcutaneous</strong><strong> Tissue Disorders</strong></p></td><td style="vertical-align:top"><p>bullous eruptions to include: Stevens-Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme, photosensitivity/phototoxicity reaction, leukocytoclastic vasculitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular</strong><strong> </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>vasodilation, vasculitis, DIC</p></td></tr></tbody></table><p>&nbsp;</p><p>‐ To report any side effects:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Saudi Arabia:</em></strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><ul><li>Fax: +966‐11‐205‐7662</li><li>Call NPC at +966‐11‐2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.</li><li>Toll free phone: 8002490000</li><li>E‐mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc</li></ul></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Other</em></strong><strong><em> </em></strong><strong><em>GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.</p></td></tr></tbody></table><p>&nbsp;</p><p>In the event of an acute overdosage, activated charcoal may be administered to aid in the removal of unabsorbed drug. General supportive measures are recommended. The patient should be observed, including ECG monitoring (see <strong>ACTION AND CLINICAL PHARMACOLOGY, Pharmacodynamics, </strong>Studies Measuring Effects on QT and Corrected QT (QTc) Intervals), and appropriate hydration maintained. Treatment should be supportive. Levofloxacin is not efficiently removed by hemodialysis or peritoneal dialysis.</p><p>&nbsp;</p><p>Levofloxacin exhibits a low potential for acute toxicity. Mice, rats, dogs and monkeys exhibited the following clinical signs after receiving a single high dose of levofloxacin: ataxia, ptosis, decreased locomotor activity, dyspnea, prostration, tremors, and convulsions. Doses in excess of 1500 mg/kg orally produced significant mortality in rodents.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Studies Measuring Effects on QT and Corrected QT (QTc) Intervals</u></p><p>Two studies have been conducted to assess specifically the effect of levofloxacin on QT and corrected QT (QTc) intervals in healthy adult volunteers. In a dose escalation study (n=48) where the effect on average QTc, after single doses of 500, 1000, and 1500 mg of levofloxacin, was measured between the baseline QTc (calculated as the average QTc measured 24, 20, 16 hours and immediately before treatment) and the average post-dose QTc interval (calculated from measurements taken every half hour for two hours and at 4, 8, 12 and 24 hours after treatment), an effect on the average QTc (Bazett) was -1.84, 1.55 and 6.40 msec, respectively. In a study which compared the effect of 3 antimicrobials (n=48) where the difference was measured between the baseline QTc (calculated as the average QTc measured 24, 20, 16 hours and immediately before treatment) and the average post-dose QTc interval (calculated from measurements taken every half hour for four hours and at 8, 12 and 24 hours after treatment), an effect on the average QTc was an increase of 3.58 msec after the 1000 mg dose of levofloxacin. The mean increase compared to baseline of QTc at Cmax in these two trials was 7.82 msec and 5.32 msec after a single 1000 mg dose. In these trials, no effect on QT intervals compared to placebo was evident at any of the doses studied. The clinical relevance of the results of these studies is not known (see <strong><em>Product Monograph Part II: </em>DETAILED PHARMACOLOGY, <u>Human Pharmacology, Studies Measuring the</u> <u>Effects on QT and Corrected QT (QTc) Intervals</u></strong>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The mean (&plusmn; SD) pharmacokinetic parameters of levofloxacin determined under single and steady-state conditions following oral (p.o.) or intravenous (i.v.) doses of levofloxacin are summarized in Table 1.5.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top" colspan="9"><p><strong>Table 1.5: Summary of Pharmacokinetic Parameters (mean &plusmn; SD)</strong></p></td></tr><tr><td style="vertical-align:top" rowspan="2"><p><strong>Regimen</strong></p></td><td style="vertical-align:top" rowspan="2"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>C</strong><strong>max</strong></p></td><td style="vertical-align:top"><p><strong>T</strong><strong>max</strong></p></td><td style="vertical-align:top"><p><strong>AUC</strong><strong>j</strong></p></td><td style="vertical-align:top"><p><strong>CL/F</strong></p></td><td style="vertical-align:top"><p><strong>Vd/F</strong></p></td><td style="vertical-align:top"><p><strong>T</strong><strong>&frac12;</strong></p></td><td style="vertical-align:top"><p><strong>Cl</strong><strong>r</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>(mcg/mL)</strong></p></td><td style="vertical-align:top"><p><strong>(h)</strong></p></td><td style="vertical-align:top"><p><strong>(mcg&bull;h/mL)</strong></p></td><td style="vertical-align:top"><p><strong>(mL/min)</strong></p></td><td style="vertical-align:top"><p><strong>(L)</strong></p></td><td style="vertical-align:top"><p><strong>(h)</strong></p></td><td style="vertical-align:top"><p><strong>(mL/min)</strong></p></td></tr><tr><td style="vertical-align:top" colspan="9"><p><strong>Single dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>250 mg p.o.a</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>2.8 &plusmn; 0.4</p></td><td style="vertical-align:top"><p>1.6 &plusmn; 1.0</p></td><td style="vertical-align:top"><p>27.2 &plusmn; 3.9</p></td><td style="vertical-align:top"><p>156 &plusmn; 20</p></td><td style="vertical-align:top"><p>ND</p></td><td style="vertical-align:top"><p>7.3 &plusmn; 0.9</p></td><td style="vertical-align:top"><p>142 &plusmn; 21</p></td></tr><tr><td style="vertical-align:top"><p>500 mg p.o.a*</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>5.1 &plusmn; 0.8</p></td><td style="vertical-align:top"><p>1.3 &plusmn; 0.6</p></td><td style="vertical-align:top"><p>47.9 &plusmn; 6.8</p></td><td style="vertical-align:top"><p>178 &plusmn; 28</p></td><td style="vertical-align:top"><p>ND</p></td><td style="vertical-align:top"><p>6.3 &plusmn; 0.6</p></td><td style="vertical-align:top"><p>103 &plusmn; 30</p></td></tr><tr><td style="vertical-align:top"><p>500 mg i.v.a</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>6.2 &plusmn; 1.0</p></td><td style="vertical-align:top"><p>1.0 &plusmn; 0.1</p></td><td style="vertical-align:top"><p>48.3 &plusmn; 5.4</p></td><td style="vertical-align:top"><p>175 &plusmn; 20</p></td><td style="vertical-align:top"><p>90 &plusmn; 11</p></td><td style="vertical-align:top"><p>6.4 &plusmn; 0.7</p></td><td style="vertical-align:top"><p>112 &plusmn; 25</p></td></tr><tr><td style="vertical-align:top"><p>750 mg p.o.cc</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>7.1 &plusmn; 1.4</p></td><td style="vertical-align:top"><p>1.9 &plusmn; 0.7</p></td><td style="vertical-align:top"><p>82.2 &plusmn; 14.3</p></td><td style="vertical-align:top"><p>157 &plusmn; 28</p></td><td style="vertical-align:top"><p>90 &plusmn; 14</p></td><td style="vertical-align:top"><p>7.7 &plusmn; 1.3</p></td><td style="vertical-align:top"><p>118 &plusmn; 28</p></td></tr><tr><td style="vertical-align:top"><p>750 mg i.v.c</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>7.99 &plusmn; 1.2b</p></td><td style="vertical-align:top"><p>ND</p></td><td style="vertical-align:top"><p>74.4 &plusmn; 8.0</p></td><td style="vertical-align:top"><p>170 &plusmn; 19</p></td><td style="vertical-align:top"><p>97.0 &plusmn; 14.8</p></td><td style="vertical-align:top"><p>7.5 &plusmn; 1.9</p></td><td style="vertical-align:top"><p>ND</p></td></tr><tr><td style="vertical-align:top" colspan="9"><p><strong>Multiple dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>500 mg q24h p.o.a</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>5.7 &plusmn; 1.4</p></td><td style="vertical-align:top"><p>1.1 &plusmn; 0.4</p></td><td style="vertical-align:top"><p>47.5 &plusmn; 6.7x</p></td><td style="vertical-align:top"><p>175 &plusmn; 25</p></td><td style="vertical-align:top"><p>102 &plusmn; 22</p></td><td style="vertical-align:top"><p>7.6 &plusmn; 1.6</p></td><td style="vertical-align:top"><p>116 &plusmn; 31</p></td></tr><tr><td style="vertical-align:top"><p>500 mg q24h i.v.a</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>6.4 &plusmn; 0.8</p></td><td style="vertical-align:top"><p>ND</p></td><td style="vertical-align:top"><p>54.6 &plusmn; 11.1x</p></td><td style="vertical-align:top"><p>158 &plusmn; 29</p></td><td style="vertical-align:top"><p>91 &plusmn; 12</p></td><td style="vertical-align:top"><p>7.0 &plusmn; 0.8</p></td><td style="vertical-align:top"><p>99 &plusmn; 28</p></td></tr><tr><td style="vertical-align:top"><p>500 mg or 250 mg q24h</p><p>i.v. patients</p></td><td style="vertical-align:top"><p>272</p></td><td style="vertical-align:top"><p>8.7 &plusmn; 4.0i</p></td><td style="vertical-align:top"><p>ND</p></td><td style="vertical-align:top"><p>72.5 &plusmn; 51.2i,x</p></td><td style="vertical-align:top"><p>154&plusmn;72</p></td><td style="vertical-align:top"><p>111 &plusmn; 58</p></td><td style="vertical-align:top"><p>ND</p></td><td style="vertical-align:top"><p>ND</p></td></tr><tr><td style="vertical-align:top"><p>with bacterial infectionsd</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>750 mg q24h p.o.cc</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>8.6 &plusmn; 1.9</p></td><td style="vertical-align:top"><p>1.4 &plusmn; 0.5</p></td><td style="vertical-align:top"><p>90.7 &plusmn; 17.6</p></td><td style="vertical-align:top"><p>143 &plusmn; 29</p></td><td style="vertical-align:top"><p>100 &plusmn; 16</p></td><td style="vertical-align:top"><p>8.8 &plusmn; 1.5</p></td><td style="vertical-align:top"><p>116 &plusmn; 28</p></td></tr><tr><td style="vertical-align:top"><p>750 mg q24h i.v.c</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>7.92 &plusmn; 0.91b</p></td><td style="vertical-align:top"><p>ND</p></td><td style="vertical-align:top"><p>72.5 &plusmn; 0.8x</p></td><td style="vertical-align:top"><p>172 &plusmn; 2</p></td><td style="vertical-align:top"><p>111 &plusmn; 12</p></td><td style="vertical-align:top"><p>8.1 &plusmn; 2.1</p></td><td style="vertical-align:top"><p>ND</p></td></tr><tr><td style="vertical-align:top" colspan="9"><p><strong>500 mg p.o. single dose, effects of gender and age:</strong></p></td></tr><tr><td style="vertical-align:top"><p>malee</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>5.5 &plusmn; 1.1</p></td><td style="vertical-align:top"><p>1.2 &plusmn; 0.4</p></td><td style="vertical-align:top"><p>54.4 &plusmn; 18.9</p></td><td style="vertical-align:top"><p>166 &plusmn; 44</p></td><td style="vertical-align:top"><p>89 &plusmn; 13</p></td><td style="vertical-align:top"><p>7.5 &plusmn; 2.1</p></td><td style="vertical-align:top"><p>126 &plusmn; 38</p></td></tr><tr><td style="vertical-align:top"><p>femalef</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>7.0 &plusmn; 1.6</p></td><td style="vertical-align:top"><p>1.7 &plusmn; 0.5</p></td><td style="vertical-align:top"><p>67.7 &plusmn; 24.2</p></td><td style="vertical-align:top"><p>136 &plusmn; 44</p></td><td style="vertical-align:top"><p>62 &plusmn; 16</p></td><td style="vertical-align:top"><p>6.1 &plusmn; 0.8</p></td><td style="vertical-align:top"><p>106 &plusmn; 40</p></td></tr><tr><td style="vertical-align:top"><p>youngg</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>5.5 &plusmn; 1.0</p></td><td style="vertical-align:top"><p>1.5 &plusmn; 0.6</p></td><td style="vertical-align:top"><p>47.5 &plusmn; 9.8</p></td><td style="vertical-align:top"><p>182 &plusmn; 35</p></td><td style="vertical-align:top"><p>83 &plusmn; 18</p></td><td style="vertical-align:top"><p>6.0 &plusmn; 0.9</p></td><td style="vertical-align:top"><p>140 &plusmn; 33</p></td></tr><tr><td style="vertical-align:top"><p>elderlyh</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>7.0 &plusmn; 1.6</p></td><td style="vertical-align:top"><p>1.4 &plusmn; 0.5</p></td><td style="vertical-align:top"><p>74.7 &plusmn; 23.3</p></td><td style="vertical-align:top"><p>121 &plusmn; 33</p></td><td style="vertical-align:top"><p>67 &plusmn; 19</p></td><td style="vertical-align:top"><p>7.6 &plusmn; 2.0</p></td><td style="vertical-align:top"><p>91 &plusmn; 29</p></td></tr><tr><td style="vertical-align:top" colspan="9"><p><strong>500 mg p.o. single dose, patients with renal insufficiency:</strong></p></td></tr><tr><td style="vertical-align:top"><p>ClCr&nbsp;50-80 mL/min</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>7.5 &plusmn; 1.8</p></td><td style="vertical-align:top"><p>1.5 &plusmn; 0.5</p></td><td style="vertical-align:top"><p>95.6 &plusmn; 11.8</p></td><td style="vertical-align:top"><p>88 &plusmn; 10</p></td><td style="vertical-align:top"><p>ND</p></td><td style="vertical-align:top"><p>9.1 &plusmn; 0.9</p></td><td style="vertical-align:top"><p>57 &plusmn; 8</p></td></tr><tr><td style="vertical-align:top"><p>ClCr&nbsp;20-49 mL/min</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>7.1 &plusmn; 3.1</p></td><td style="vertical-align:top"><p>2.1 &plusmn; 1.3</p></td><td style="vertical-align:top"><p>182.1 &plusmn; 62.6</p></td><td style="vertical-align:top"><p>51 &plusmn; 19</p></td><td style="vertical-align:top"><p>ND</p></td><td style="vertical-align:top"><p>27 &plusmn; 10</p></td><td style="vertical-align:top"><p>26 &plusmn; 13</p></td></tr><tr><td style="vertical-align:top"><p>ClCr&nbsp;&lt; 20 mL/min</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>8.2 &plusmn; 2.6</p></td><td style="vertical-align:top"><p>1.1 &plusmn; 1.0</p></td><td style="vertical-align:top"><p>263.5 &plusmn; 72.5</p></td><td style="vertical-align:top"><p>33 &plusmn; 8</p></td><td style="vertical-align:top"><p>ND</p></td><td style="vertical-align:top"><p>35 &plusmn; 5</p></td><td style="vertical-align:top"><p>13 &plusmn; 3</p></td></tr><tr><td style="vertical-align:top"><p>Hemodialysis</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>5.7 &plusmn; 1.0</p></td><td style="vertical-align:top"><p>2.8 &plusmn; 2.2</p></td><td style="vertical-align:top"><p>ND</p></td><td style="vertical-align:top"><p>ND</p></td><td style="vertical-align:top"><p>ND</p></td><td style="vertical-align:top"><p>76 &plusmn; 42</p></td><td style="vertical-align:top"><p>ND</p></td></tr><tr><td style="vertical-align:top"><p>CAPD</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>6.9 &plusmn; 2.3</p></td><td style="vertical-align:top"><p>1.4 &plusmn; 1.1</p></td><td style="vertical-align:top"><p>ND</p></td><td style="vertical-align:top"><p>ND</p></td><td style="vertical-align:top"><p>ND</p></td><td style="vertical-align:top"><p>51 &plusmn; 24</p></td><td style="vertical-align:top"><p>ND</p></td></tr><tr><td style="vertical-align:top" colspan="9"><p><strong>750 mg i.v. single dose and multiple dose, patients with renal insufficiency</strong></p></td></tr><tr><td style="vertical-align:top"><p>Single dose ‐ CICR&nbsp;50‐80 mL/mink</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>13.3 &plusmn; 3.6</p></td><td style="vertical-align:top"><p>ND</p></td><td style="vertical-align:top"><p>128 &plusmn; 37</p></td><td style="vertical-align:top"><p>104 &plusmn; 25</p></td><td style="vertical-align:top"><p>62.7 &plusmn; 15.1</p></td><td style="vertical-align:top"><p>7.5 &plusmn; 1.5</p></td><td style="vertical-align:top"><p>ND</p></td></tr><tr><td style="vertical-align:top"><p>Multiple q24h dose ‐ CICr&nbsp;50‐80 mL/mink</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>14.3 &plusmn; 3.2</p></td><td style="vertical-align:top"><p>ND</p></td><td style="vertical-align:top"><p>145 &plusmn; 36</p></td><td style="vertical-align:top"><p>103 &plusmn; 20</p></td><td style="vertical-align:top"><p>64.2 &plusmn; 16.9</p></td><td style="vertical-align:top"><p>7.8 &plusmn; 2.0</p></td><td style="vertical-align:top"><p>ND</p></td></tr></tbody></table><p>a healthy males 18-53 years of age;</p><p>b 60 min infusion for 250 mg and 500 mg doses, 90 min infusion for 750 mg dose;</p><p>c healthy male subjects 32-46 years of age;</p><p>cc healthy male subjects 19-51 years of age;</p><p>d including 500 mg q48h for 8 patients with moderate renal impairment (ClCr20-50 mL/min) and infections of the respiratory tract or skin;</p><p>e healthy males 22-75 years of age;</p><p>f healthy females 18-80 years of age;</p><p>g young healthy male and female subjects 18-36 years of age;</p><p>h healthy elderly male and female subjects 66-80 years of age;</p><p>i dose-normalized values (to 500 mg dose), estimated by population pharmacokinetic modelling;</p><p>j AUC for 0-&infin; reported, unless otherwise specified;</p><p>k male and female subjects 34-54 years of age;</p><p>x AUC 0-24 h;</p><p>* Absolute bioavailability; F = 0.99 &plusmn; 0.08 from a 500 mg tablet and F = 0.99 &plusmn; 0.06 from a 750 mg tablet.</p><p>ND = Not Determined</p><p>&nbsp;</p><p><strong>Absorption:</strong></p><p><u>Oral</u></p><p>Levofloxacin is rapidly and essentially completely absorbed after oral administration. Peak plasma concentrations are usually attained 1 to 2 hours after oral dosing. The absolute bioavailability of a 500 mg tablet and a 750 mg tablet of levofloxacin is approximately 99% in both cases, demonstrating complete oral absorption of levofloxacin. Levofloxacin pharmacokinetics are linear and predictable after single and multiple oral dosing regimens. Steady-state conditions are reached within 48 hours following a 500 mg or 750 mg once-daily dosage regimen. The peak and trough plasma concentrations attained following multiple once-daily oral dosage regimens were approximately 5.7 mcg/mL and 0.5 mcg/mL after the 500 mg doses, and 8.6 mcg/mL and 1.1 mcg/mL after the 750 mg doses, respectively.</p><p>&nbsp;</p><p>There was no clinically significant effect of food on the extent of absorption of levofloxacin. Oral administration with food slightly prolongs the time to peak concentration by approximately 1 hour, and slightly decreases the peak concentration by approximately 14%. Therefore, levofloxacin can be administered without regard to food.</p><p>&nbsp;</p><p><strong>Distribution:</strong></p><p>The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues. Levofloxacin reaches its peak levels in skin tissues (11.7 mcg/g for a 750 mg dose) and in blister fluid (4.33 mcg/g for a 500 mg dose) at approximately 3 to 4 hours after dosing. The skin tissue biopsy to plasma AUC ratio is approximately 2. The blister fluid to plasma AUC ratio is approximately 1, following multiple once-daily oral administration of 750 mg and 500 mg levofloxacin to healthy subjects, respectively.</p><p>Levofloxacin also penetrates into lung tissues. Lung tissue concentrations were generally 2- to 5-fold higher than plasma concentrations, and ranged</p><p>from approximately 2.4 to 11.3 mcg/g over a 24-hour period after a single 500 mg oral dose. Levofloxacin is 24 to 38% bound to serum proteins across all species studied. Levofloxacin binding to serum proteins is independent of the drug concentration.</p><p>&nbsp;</p><p><strong>Metabolism:</strong></p><p>Levofloxacin is stereochemically stable in plasma and urine, and does not invert metabolically to its enantiomer, D-ofloxacin. Levofloxacin undergoes limited metabolism in humans, and is primarily excreted as unchanged drug (87%) in the urine within 48 hours.</p><p>&nbsp;</p><p><strong>Excretion:</strong></p><p>The major route of elimination of levofloxacin in humans is as unchanged drug in the urine. The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally.</p><p>&nbsp;</p><p><strong><u>Special Populations and Conditions</u></strong></p><p><strong>Pediatrics: </strong>The pharmacokinetics of levofloxacin in pediatric patients have not been studied.</p><p>&nbsp;</p><p><strong>Geriatrics:</strong><strong> </strong>There are no significant differences in levofloxacin pharmacokinetics between young and elderly subjects when the subjects&rsquo; differences in creatinine clearance are taken into consideration. Drug absorption appears to be unaffected by age. Levofloxacin dose adjustment based on age alone is not necessary.</p><p>&nbsp;</p><p><strong>Gender: </strong>There are no significant differences in levofloxacin pharmacokinetics between male and female subjects when the differences in creatinine clearance are taken into consideration. Dose adjustment based on gender alone is not necessary.</p><p>&nbsp;</p><p><strong>Race: </strong>The apparent total body clearance and apparent volume of distribution were not affected by race in a covariate analysis performed on data from 72 subjects.</p><p>&nbsp;</p><p><strong>Hepatic Insufficiency: </strong>Pharmacokinetic studies in hepatically impaired patients have not been conducted. Due to the limited extent of levofloxacin metabolism, the pharmacokinetics of levofloxacin are not expected to be affected by hepatic impairment.</p><p>&nbsp;</p><p><strong>Renal Insufficiency: </strong>Pharmacokinetic parameters of levofloxacin following oral or intravenous doses of levofloxacin in patients with impaired renal function (creatinine clearance &le;80 mL/min) are presented in Table 1.5. Clearance of levofloxacin is reduced and plasma elimination half-life is prolonged in this patient population. Dosage adjustment may be required in such patients to avoid accumulation.</p><p>A dosage reduction is being recommended depending on the levels of renal insufficiency. Dosing recommendations are based on pharmacokinetic modelling of data collected from a clinical safety and pharmacokinetic study in renally impaired patients treated with a single 500 mg oral dose of levofloxacin (see <strong>WARNINGS AND PRECAUTIONS, <u>Renal, </u></strong>and <strong>DOSAGE AND ADMINISTRATION, Recommended Dose and Dosage Adjustment, </strong>Patients with Impaired <u>Renal</u> <u>Function)</u>.</p><p>Neither hemodialysis nor continuous ambulatory peritoneal dialysis (CAPD) is effective in removal of levofloxacin from the body, indicating supplemental doses of levofloxacin are not required following hemodialysis or CAPD.</p><p>&nbsp;</p><p><strong>Bacterial Infection: </strong>The pharmacokinetics of levofloxacin in patients with community-acquired bacterial infections are comparable to those observed in healthy subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The potential toxicity of levofloxacin has been evaluated in acute, sub-chronic, carcinogenicity, mutagenicity, reproduction and teratology, and special toxicity studies.</p><p>&nbsp;</p><p><strong><u>Acute Toxicity</u></strong></p><p><strong>Table</strong><strong> </strong><strong>2.49</strong><strong> </strong><strong>- Summary of the acute toxicity studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>STRAIN/</strong><strong> </strong><strong>SPECIES</strong></p></td><td style="vertical-align:top"><p><strong># ANIMAL/ GROUP</strong></p></td><td style="vertical-align:top"><p><strong>ROUTE</strong></p></td><td style="vertical-align:top"><p><strong>LD</strong><strong>50</strong></p><p><strong>mg/kg</strong></p></td><td style="vertical-align:top"><p><strong>SUMMARY</strong><strong> </strong><strong>TOXIC</strong><strong> </strong><strong>SIGNS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mouse</p></td><td style="vertical-align:top"><p>M-10 F-10</p></td><td style="vertical-align:top"><p>p.o.</p></td><td style="vertical-align:top"><p>1881</p><p>1803</p></td><td style="vertical-align:top"><p>&darr; locomotor activity, ptosis, respiratory depression, tremor, convulsion</p></td></tr><tr><td style="vertical-align:top"><p>Mouse</p></td><td style="vertical-align:top"><p>M-10</p></td><td style="vertical-align:top"><p>p.o.</p></td><td style="vertical-align:top"><p>1943</p></td><td style="vertical-align:top"><p>&darr; locomotor activity, ptosis, prostration, tremor, convulsion</p></td></tr><tr><td style="vertical-align:top"><p>Rat</p></td><td style="vertical-align:top"><p>M-10 F-10</p></td><td style="vertical-align:top"><p>p.o.</p></td><td style="vertical-align:top"><p>1478</p><p>1507</p></td><td style="vertical-align:top"><p>salivation, ptosis, &darr; locomotor activity, tremor, convulsion, respiratory depression</p></td></tr><tr><td style="vertical-align:top"><p>Rat</p></td><td style="vertical-align:top"><p>M-10</p></td><td style="vertical-align:top"><p>p.o.</p></td><td style="vertical-align:top"><p>1754</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Monkey</p></td><td style="vertical-align:top"><p>F-2</p></td><td style="vertical-align:top"><p>p.o.</p></td><td style="vertical-align:top"><p>&gt;250</p></td><td style="vertical-align:top"><p>soft stool, transient &darr;platelet count and &uarr; bw at 250 mg/kg, transient &uarr; bilirubin, &darr; bw, and emesis at 500 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Mouse</p></td><td style="vertical-align:top"><p>M-10 F-10</p></td><td style="vertical-align:top"><p>i.v.</p></td><td style="vertical-align:top"><p>268</p><p>323</p></td><td style="vertical-align:top"><p>&darr; locomotor activity, ptosis, abnormal posture, tachypnea, convulsion, dyspnea</p></td></tr><tr><td style="vertical-align:top"><p>Mouse</p></td><td style="vertical-align:top"><p>M-5</p></td><td style="vertical-align:top"><p>i.v.</p></td><td style="vertical-align:top"><p>244</p></td><td style="vertical-align:top"><p>symptoms prior to death: tachypnea, collapse, dyspnea, convulsions, respiratory arrest. In survivors,&darr; locomotor activity and collapse</p></td></tr><tr><td style="vertical-align:top"><p>Rat</p></td><td style="vertical-align:top"><p>M-10 F-10</p></td><td style="vertical-align:top"><p>i.v.</p></td><td style="vertical-align:top"><p>423</p><p>395</p></td><td style="vertical-align:top"><p>&darr; locomotor activity, prostration followed by respiratory depression, tachypnea, dyspnea, convulsion, tremor, salivation</p></td></tr><tr><td style="vertical-align:top"><p>Dog</p></td><td style="vertical-align:top"><p>F-2</p></td><td style="vertical-align:top"><p>i.v.</p></td><td style="vertical-align:top"><p>200</p></td><td style="vertical-align:top"><p>salivation, dyspnea, tonic and clonic convulsion, death from respiratory arrest at 200 mg/kg, lacrimation, vomiting, lethargy, and tremors. &uarr; RBC, WBC, ALT and ALP, and &darr; P on Day 2. Values returned to normal by Day 8.</p></td></tr><tr><td style="vertical-align:top"><p>Monkey</p></td><td style="vertical-align:top"><p>F-2</p></td><td style="vertical-align:top"><p>i.v.</p></td><td style="vertical-align:top"><p>&gt;200</p></td><td style="vertical-align:top"><p>at 200 mg/kg &ndash; ptosis, vomiting, &darr; locomotor activity, prostration and anorexia, ketone urine, proteinuria, &darr; glucose. Ptosis, and emesis at 100 mg/kg.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Signs of acute toxicity with metabolites (desmethyl and N-oxide) were similar to that of levofloxacin and were produced at doses significantly greater than would be encountered with therapeutic use.</p><p>&nbsp;</p><p><strong><u>Sub-Chronic Toxicity</u></strong></p><p><strong>&nbsp;</strong></p><p><strong>Table 2.50 - Summary of the sub-chronic toxicity studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Species,</strong><strong> </strong><strong>Age/Grp/No.,</strong><strong> </strong><strong>Sex/Grp</strong></p></td><td style="vertical-align:top"><p><strong>Route, Dosage, Duration</strong></p></td><td style="vertical-align:top"><p><strong>Results</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rat</p><p>4-6 wk old</p><p>4 grp</p><p>10 ♀ &amp; 10 ♂/ grp</p></td><td style="vertical-align:top"><p>p.o.</p><p>0, 50, 200, 800</p><p>4 weeks</p></td><td style="vertical-align:top"><p><strong>Lethality</strong>: No treatment-related deaths. <strong>Clin Obs</strong>: Salivation, body staining, transient pallor and hypothermia at 800 mg/kg. Transient &darr; fc in treated ♂ and &darr; bw gain during week 1 in ♂ at 800 mg/kg.</p><p><strong>Clin Path</strong>: &uarr; WBC due to &uarr; in lymphocytes at 800 mg/kg. PMNs &darr; in treated ♀ and at 50 and 200 mg/kg in ♂. &darr; K+, Cl-, and urea and</p><p>&uarr; P and ALT (primarily at 800 mg/kg). Higher M:E ratio at 800 mg/kg. <strong>Micro</strong>: &darr; relative heart weights at 800 mg/kg and &uarr; cecal weights at 200 and 800 mg/kg. Slight vacuolization and minimal hypertrophy of hepatocytes at 800 mg/kg and arthropathy (minor) at 800 mg/kg.</p><p>NOAEL = 200 mg/kg/day. TI = 2.8</p></td></tr><tr><td style="vertical-align:top"><p>Rat</p><p>4-5 wk old</p><p>4 grp</p><p>20 ♀ &amp; 20 ♂/ grp</p></td><td style="vertical-align:top"><p>p.o.</p><p>0, 20, 80, 320</p><p>26 wk</p></td><td style="vertical-align:top"><p><strong>Lethality</strong>: No treatment-related deaths. <strong>Clin Obs</strong>: Salivation, &uarr; large fecal pellets and stained haircoat mainly at 320 mg/kg. &uarr; fc at 80 and 320 mg/kg, &uarr; food conversion ratios in ♀ at 320 mg/kg.</p><p><strong>Clin Path</strong>: &darr; PMNs in all treated rats, &uarr; glucose (treated ♂), &darr; triglycerides (320 mg/kg ♀) &darr; b-globulin (treated rats), &darr; a- globulin (treated ♀), &darr; Cl-&nbsp;(320 mg/kg rats and 80 mg/kg ♀), &darr; total protein (80 and 320 mg/kg ♂) and &uarr; urinary pH at 80 and 320 mg/kg. <strong>Micro</strong>: Dosage-related &uarr; cecal weight, elongated and/or distended ceca and engorged goblet cells of the cecal mucosa.</p><p>Changes in intestinal flora and lower nutrient absorption in the intestines probably responsible for most changes. No arthropathy. NOAEL = 20 mg/kg/day. TI = 2.8</p></td></tr><tr><td style="vertical-align:top"><p>Rat</p></td><td style="vertical-align:top"><p>Diet</p></td><td style="vertical-align:top"><p><strong>Lethality</strong>: No deaths. <strong>Clin Obs: </strong>&darr; bw at 400 and 800 mg/kg<strong>.</strong></p></td></tr><tr><td style="vertical-align:top"><p>6 wk old</p></td><td style="vertical-align:top"><p>0, 100, 200,</p></td><td style="vertical-align:top"><p><strong>Clin Path</strong>: &darr; total protein (&ge; 200 mg/kg), globulin and triglycerides</p></td></tr><tr><td style="vertical-align:top"><p>5 grp</p></td><td style="vertical-align:top"><p>400, 800</p></td><td style="vertical-align:top"><p>(at 800 mg/kg ♂ only). &uarr; ALP at 800 mg/kg (♀). <strong>Micro</strong>: &darr; absolute</p></td></tr><tr><td style="vertical-align:top" rowspan="2"><p>10 ♀ &amp; 10 ♂/ grp</p></td><td style="vertical-align:top" rowspan="2"><p>13 wk</p></td><td style="vertical-align:top"><p>liver weight &ge;400 (♂), &uarr; cecal weight and cecal distension (&ge;100).</p></td></tr><tr><td style="vertical-align:top"><p>No arthropathy. NOAEL = 100 mg/kg/day. TI = 14</p></td></tr><tr><td style="vertical-align:top"><p>Rat</p><p>4 wk old</p><p>3 grp</p><p>5 ♂/ grp</p></td><td style="vertical-align:top"><p>i.v.</p><p>0, 20, 100</p><p>10 days</p></td><td style="vertical-align:top"><p>NSF</p></td></tr><tr><td style="vertical-align:top"><p>Rat</p><p>4 wk old</p><p>4 grp</p><p>4 ♂/ grp</p></td><td style="vertical-align:top"><p>i.v.</p><p>0, 10, 40, 160</p><p>2 wk</p></td><td style="vertical-align:top"><p><strong>Lethality</strong>: No mortality. <strong>Clin Obs</strong>: NSF. <strong>Clin Path and Micro</strong>: Crystalluria, &uarr; cecal weight and &darr; (mild) AST and ALT at 160 mg/kg. No arthropathy.</p><p>NOAEL = 40 mg/kg/day. TI = 5.6</p></td></tr><tr><td style="vertical-align:top"><p>Rat</p><p>5 wk old</p><p>4 grp</p><p>10 ♀ &amp; 10 ♂/ grp</p></td><td style="vertical-align:top"><p>i.v.</p><p>0, 20, 60, 180</p><p>4 wk</p></td><td style="vertical-align:top"><p><strong>Lethality</strong>: No mortality. <strong>Clin Obs</strong>: Transient &darr; spontaneous activity, blepharoptosis (♂), &darr; bw gain and fc, and swelling at the injection site at 180 mg/kg. <strong>Clin Path</strong>: &darr; total protein, albumin, A/G ratio, cholinesterase activity, urinary protein and RBC. &uarr; WBC, retic and fibrinogen at 180 mg/kg. Crystalluria. <strong>Micro</strong>:</p><p>&darr;weights of thymus, liver, heart, ovaries, and brain due to &darr; bw gain. &uarr; cecal weight at 60 and 180 mg/kg. Arthropathy at 60 and 180 mg/kg.</p><p>NOAEL = 20 mg/kg/day. TI = 2.8</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Rat</p><p>6 wk old</p><p>4 grp</p><p>10 ♀ &amp; 10 ♂/ grp</p></td><td style="vertical-align:top"><p>i.v.</p><p>0, 10, 30, 90</p><p>13 wk</p></td><td style="vertical-align:top"><p><strong>Lethality</strong>: None. <strong>Clin Obs</strong>: Slight &darr; fc at 30 and 90 mg/kg (♂).</p><p><strong>Clin Path</strong>: Mild &darr; total protein, phospholipids and cholesterol at 90 mg/kg (♂) due to &darr; fc. Mild &uarr; A/G and albumin at 30 and 90 mg/kg (♂). Crystalluria at 30 and 90 (♂) and 90 mg/kg (♀).<strong>Micro</strong>: &uarr; cecal weight, arthropathy (mild) at 90 mg/kg.</p><p>NOAEL = 30 mg/kg/day. TI = 4.2</p></td></tr><tr><td style="vertical-align:top"><p>Dog</p><p>4-5 mo old</p><p>5 grp</p><p>3 ♂/ grp</p></td><td style="vertical-align:top"><p>i.v.</p><p>0, 2, 4, 15, 60</p><p>2 wk</p></td><td style="vertical-align:top"><p><strong>Lethality</strong>: None. <strong>Clin Obs</strong>: Histamine-like effects at 15 and 60 mg/kg, &darr; bw gain and fc at 60 mg/kg. <strong>Clin Path</strong>: &darr; plasma fibrinogen and urine specific gravity;&darr; serum Fe. <strong>Micro</strong>: &darr; absolute liver weight at 60 mg/kg and &darr; absolute and relative testes weight at 4, 15 and 60 mg/kg; and thrombus formation in injected vessels at 60 mg/kg, arthropathy and delayed testicular maturation at &ge; 4 mg/kg. NOAEL = 2 mg/kg/day. TI= 0.28</p></td></tr><tr><td style="vertical-align:top"><p>Dog</p><p>18 mo old</p><p>3 grp</p><p>3 ♂/ grp</p></td><td style="vertical-align:top"><p>i.v.</p><p>0, 10, 30</p><p>2 wk</p></td><td style="vertical-align:top"><p><strong>Lethality</strong>: None. <strong>Clin Obs</strong>: Histamine-like effects and &darr; activity at 10 and 30 mg/kg. Signs subsided by 30 min post-administration except &darr; activity. <strong>Clin Path</strong>: NSF. <strong>Micro</strong>: NSF.</p><p>NOAEL for arthropathy= 30 mg/kg/day. TI = 4.2</p></td></tr><tr><td style="vertical-align:top"><p>Dog</p><p>7-8 mo old</p><p>4 grp</p><p>3 ♀ &amp; 3♂/ grp</p></td><td style="vertical-align:top"><p>infusion</p><p>0, 3, 10, 30</p><p>4 wk</p></td><td style="vertical-align:top"><p><strong>Lethality</strong>: None. <strong>Clin Obs</strong>: Histamine-like effects in a dosage- related manner. <strong>Clin Path</strong>: NSF. <strong>Micro</strong>: Arthropathy at &ge; 10 mg/kg/day</p><p>NOAEL = 3 mg/kg/day. TI = 0.42</p></td></tr><tr><td style="vertical-align:top"><p>Monkey</p><p>2-4 yr old</p><p>4 grp</p><p>3 ♀ &amp; 4♂/ grp</p></td><td style="vertical-align:top"><p>p.o.</p><p>0, 10, 30, 100</p><p>4 wk</p></td><td style="vertical-align:top"><p><strong>Lethality</strong>: None. <strong>Clin Obs and Clin Path</strong>: Salivation and diarrhea at 100 mg/kg. Some animals occasionally had what appeared to be</p><p>blood in the urine. Slight bw losses, unusually large adrenal glands in one monkey and low urinary pH in two monkeys at 100 mg/kg/day. <strong>Micro</strong>: NSF.</p><p>NOAEL = 30 mg/kg/day. TI = 4.2</p></td></tr><tr><td style="vertical-align:top"><p>Monkey</p><p>2-4 yr old</p><p>4 grp</p><p>4 ♀ &amp; 4♂/ grp</p></td><td style="vertical-align:top"><p>p.o.</p><p>0, 10, 25, 62.5</p><p>26 wk</p></td><td style="vertical-align:top"><p><strong>Lethality</strong>: None. <strong>Clin Obs</strong>: &darr; fc in one high-dosage male during the first half of the study. <strong>Clin Path and Micro</strong>: NSF.</p><p>NOAEL = 62.5 mg/kg/day. TI = 8.75</p></td></tr><tr><td style="vertical-align:top"><p>Monkey</p><p>2-4 yr old</p><p>4 grp</p><p>3 ♀ &amp; 3♂/ grp</p></td><td style="vertical-align:top"><p>i.v.</p><p>0, 10, 25, 63</p><p>4 wk</p></td><td style="vertical-align:top"><p><strong>Lethality</strong>: None. <strong>Clin Obs</strong>: Loose stools and slightly &darr; wc at 25 and 63 mg/kg and ptosis, occasional quietness and &darr;fc (♀) at 63 mg/kg. <strong>Clin Path</strong>: NSF. <strong>Micro</strong>: NSF.</p><p>NOAEL = 10 mg/kg/day. TI = 1.4</p></td></tr></tbody></table><p>Dosage = mg/kg/day; Clin Obs = clinical observations; Clin Path = clinical pathology; Micro = macroscopic and microscopic findings; NOAEL = No Observable Adverse Effect Level; NSF = No Significant Findings; TI =</p><p>Therapeutic Index &ndash; relationship of toxic dose to the projected human dose (calculation based on maximum daily dose of 500 mg and body weight of 70 kg); ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase; A/G = albumin/globulin; fc = food consumption; wc = water consumption; bw = body weight; RBC = red blood cells; WBC = white blood cells; retic = reticulocyte; PMN = neutrophil; M:E = myeloid:erythroid; K+&nbsp;= potassium; Cl-&nbsp;= chloride; P = phosphorus; Fe = iron.</p><p>&nbsp;</p><p><strong>Carcinogenicity</strong></p><p>Levofloxacin exhibited no carcinogenic or tumorigenic potential after dietary administration of 10, 30 or 100 mg/kg/day for 2 years in a rat carcinogenicity study. The highest dose was 1.4 or 6.7 times the highest recommended human dose (750 mg) based on surface area or body weight, respectively. The mean levofloxacin plasma concentration in the 2-year rat bioassay (at 100 mg/kg/day) was 34% of the human steady-state concentration after 500 mg b.i.d. dosing. In a 2- stage multiple organ carcinogenesis model in rats, levofloxacin at a dosage level of approximately 668 mg/kg/day in diet for 16 weeks did not promote the development of preneoplastic or</p><p>&nbsp;</p><p>neoplastic lesions after pretreatment with a number of wide spectrum carcinogens.</p><p>&nbsp;</p><p><strong>Mutagenicity</strong></p><p>Levofloxacin was not mutagenic in the following assays: Ames bacterial mutation assays (S. <em>typhimurium </em>and <em>E. coli), </em>CHO/HGPRT forward mutation assay, mouse micronucleus test, mouse dominant lethal test, rat unscheduled DNA synthesis and the mouse sister chromatid exchange (SCE) assays. It was positive in the <em>in vitro </em>chromosomal aberration (CHL cell line) and SCE assays (CHL/IU cell line).</p><p>&nbsp;</p><p><strong><u>Reproduction</u></strong><strong><u> </u></strong><strong><u>and</u></strong><strong><u> </u></strong><strong><u>Teratology</u></strong></p><p><strong>Table 2.51 - Segment I: Fertility and Reproductive Performance Studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Study</strong><strong>a</strong></p></td><td style="vertical-align:top"><p><strong>Parental Toxicity</strong></p></td><td style="vertical-align:top"><p><strong>Embryo/Fetal Toxicity</strong></p></td><td style="vertical-align:top"><p><strong>Teratogenicity</strong></p></td></tr><tr><td style="vertical-align:top"><p>Oral gavage, rat 0, 10, 60, 360</p><p>mg/kg/day 24/sex/group</p></td><td style="vertical-align:top"><p>salivation (at 60 mg/kg mostly ♂ and at 360 mg/kg ♀&amp; ♂) and soft stool at 360 mg/kg; &uarr; wc at 360 mg/kg for ♂ and &ge;60 mg/kg for ♀; &darr; in placental weights at 360 mg/kg. No effect on mating performance.</p></td><td style="vertical-align:top"><p>No effect on intrauterine survival or fetal development.</p></td><td style="vertical-align:top"><p>None</p></td></tr><tr><td style="vertical-align:top"><p>Intravenous, rat 0, 10, 30, 100</p><p>mg/kg/day 24/sex/group</p></td><td style="vertical-align:top"><p>swollen tail, soft feces and urinary incontinence at 100 mg/kg in ♂ and ♀. In females, &darr; bw gain and fc (wk 1 only) at 100 mg/kg. In males, &darr; bw gain &ge;30 and slight &darr; fc at all levels, enlarged cecum</p><p>&ge;30 mg/kg. No effect on reproductive performance.</p><p>NOAEL = 10 mg/kg/day for ♂ rats, 30 mg/kg/day for ♀ rats.</p></td><td style="vertical-align:top"><p>No effect on intrauterine</p></td><td style="vertical-align:top"><p>None</p></td></tr></tbody></table><p>wc = water consumption; bw = body weight; fc = food consumption</p><p>a In both studies, males (8 weeks old) were administered levofloxacin daily for 9 weeks prior to mating, throughout the mating period, and until necropsy. The females (11-12 weeks old) were treated daily for 2 weeks prior to mating, throughout the mating period, and for 7 days after copulation. NOAEL = No Observable Adverse Effect Levels.</p><p>&nbsp;</p><p><strong>Table 2.52 - Segment II: Teratogenicity</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Study</strong><strong>a</strong></p></td><td style="vertical-align:top"><p><strong>Maternal Toxicity</strong></p></td><td style="vertical-align:top"><p><strong>Embryo/Fetal</strong><strong> </strong><strong>Toxicity</strong></p></td><td style="vertical-align:top"><p><strong>Teratogenicity</strong></p></td></tr><tr><td style="vertical-align:top"><p>Oral gavage, rat 0, 10, 90, 810</p><p>mg/kg/day 36 ♀/group</p></td><td style="vertical-align:top"><p>salivation, piloerection, alopecia, and poor hair coat, soft stool, hyperuresis and/or watery eyes at 90 mg/kg and 810 mg/kg.</p><p>&darr; bw gain at 810 mg/kg, &darr; fc &ge;90 mg/kg, &uarr; wc at 810 mg/kg, enlarged cecum &ge; 90 mg/kg.</p><p>NOAEL = 10 mg/kg.</p></td><td style="vertical-align:top"><p>No effect on survival and weaning rate, sexual maturation, development or reproductive performance of F1 generation. &darr; mean bw for pups at birth (♂ and ♀) on days 63-77 postpartum (♀) at 810 mg/kg. &uarr; fetal mortality and &darr; fetal weight at 810 mg/kg. Maternal toxicity at 810 mg/kg led to delayed ossification of sternum, metatarsal, proximal phalange, and caudal vertebrae.</p></td><td style="vertical-align:top"><p>None</p></td></tr><tr><td style="vertical-align:top"><p>Intravenous, rat 0, 10, 40, 160</p><p>mg/kg/day 36♀/group</p></td><td style="vertical-align:top"><p>&darr; fc at 40 mg/kg (Days 7-12 only) and at 160 mg/kg. Swollen tails (inj. site) and &uarr; wc at 160 mg/kg.</p><p>NOAEL = 10 mg/kg for dams.</p></td><td style="vertical-align:top"><p>Maternal toxicity led to delayed ossification of sternum and caudal vertebrae. No effect other than delayed ossification was observed.</p><p>NOAEL = 40 mg/kg for fetuses, &ge;160 mg/kg for pups.</p></td><td style="vertical-align:top"><p>None</p></td></tr><tr><td style="vertical-align:top"><p>Oral gavage, rabbit</p><p>0, 5, 16, 50</p><p>mg/kg/day 16 ♀/group</p></td><td style="vertical-align:top"><p>&darr; fc and bw gain at 50 mg/kg, transient</p><p>&darr; fc at 16 mg/kg, &uarr; number placental remnants at 50 mg/kg, 4 dams aborted.</p><p>NOAEL = 5 mg/kg/day for dams.</p></td><td style="vertical-align:top"><p>No adverse effects.</p><p>NOAEL = 50 mg/kg/day for fetuses.</p></td><td style="vertical-align:top"><p>None</p></td></tr><tr><td style="vertical-align:top"><p>Intravenous, rabbit</p><p>0, 6.25, 12.5,</p><p>25 mg/kg/day</p><p>20 ♀/group</p></td><td style="vertical-align:top"><p>transient &darr; bw and fc at 25 mg/kg early in gestation (Days 6-9).</p><p>NOAEL = 12.5 mg/kg/day for maternal toxicity.</p></td><td style="vertical-align:top"><p>No adverse effects.</p><p>NOAEL = 25 mg/kg/day for developmental toxicity.</p></td><td style="vertical-align:top"><p>None</p></td></tr></tbody></table><p>bw = body weight; wc = water consumption; fc = food consumption; inj. = injection</p><p>a In both rat studies, the rats were dosed from Day 7 to Day 17 of gestation. NOAEL = No Observable Adverse Effect Level</p><p>&nbsp;</p><p><strong>Table 2.53 - Segment III: Perinatal and Postnatal</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Study</strong></p></td><td style="vertical-align:top"><p><strong>Maternal Toxicity</strong></p></td><td style="vertical-align:top"><p><strong>Embryo/Fetal</strong><strong> </strong><strong>Toxicity</strong></p></td><td style="vertical-align:top"><p><strong>Parturition/Neonatal</strong><strong> </strong><strong>Growth and Survival</strong></p></td></tr><tr><td style="vertical-align:top"><p>Oral gavage, rat 0, 10, 60, 360</p><p>mg/kg/day 24 ♀/group Dosed daily</p><p>from Day 17 of gestation to Day 21 of lactation</p></td><td style="vertical-align:top"><p>salivation, diarrhea and soft feces at 360 mg/kg, salivation in some at 60 mg/kg, &darr; fc at 60 mg/kg during gestation and lactation (Days 14-18), &darr; fc during gestation &uarr; fc during lactation at 360 mg/kg, &darr; wc on 2 days during gestation and &uarr; wc during lactation at 360 mg/kg.</p><p>NOAEL = 10 mg/kg for dams.</p></td><td style="vertical-align:top"><p>No effects on either F1&nbsp;or F2&nbsp;generation.</p><p>NOAEL = 360 mg/kg for pups.</p></td><td style="vertical-align:top"><p>No effects</p></td></tr></tbody></table><p>NOAEL = No Observable Adverse Effect Level</p><p>&nbsp;</p><p><strong><u>Special</u></strong><strong><u> </u></strong><strong><u>Studies</u></strong></p><p><u>Arthropathic Potential</u></p><p>Levofloxacin and other quinolones have been shown to cause arthropathy in immature animals of most species tested (see WARNINGS AND PRECAUTIONS). In juvenile rats, 7 days of oral administration of 300 mg/kg/day levofloxacin results in blister and cavity formation in articular cartilage. In juvenile dogs (4 months old), 7 days of oral administration of 10 mg/kg/day levofloxacin produces blister formation, cavitation, and increased synovial fluid of diarthroidal joints. In young immature dogs (13 months old), blister formation and cavitation of the arthritic joint were observed in 1/3 dogs following oral administration of 40 mg/kg/day levofloxacin for 7 days.</p><p>&nbsp;</p><p>In long-term multidose studies, arthropathy in rats was observed after oral administration of 800 mg/kg/day for 4 weeks, after intravenous administration at 60 mg/kg/day for 4 weeks and 90 mg/kg/day for 13 weeks. Arthropathic lesions were observed in 4-month-old dogs following 4 mg/kg/day intravenous administration for 2 weeks and in 7 to 8 month-old dogs following 10 mg/kg/day intravenous administration for 4 weeks. No arthropathy was observed following 2-week intravenous dosing at dosages up to 30 mg/kg/day in young adult dogs (18 months old).</p><p>Three-month old beagle dogs dosed orally with up to 40 mg/kg/day levofloxacin for 8 or 9 consecutive days, with an 18-week recovery period, exhibited musculoskeletal clinical signs by the final dose at dose levels &ge;2.5 mg/kg (approximately 0.2-fold the pediatric dose based upon AUC comparisons). Synovitis and articular cartilage lesions were observed at the 10 and 40 mg/kg dose levels (equivalent to and 3-fold greater than the potential therapeutic dose, respectively). All musculoskeletal clinical signs were resolved by week 5 of recovery; synovitis was resolved by the end of the 18-week recovery period; whereas, articular cartilage erosions and chondropathy persisted.</p><p>&nbsp;</p><p><strong><u>Phototoxicity</u></strong></p><p>When tested in a mouse ear swelling bioassay, levofloxacin exhibited phototoxicity similar in magnitude to ofloxacin but less phototoxicity than some of the other quinolones tested. A single oral administration of 800 mg/kg levofloxacin followed by UVA exposure has been shown to result in ear erythema and swelling.</p><p>&nbsp;</p><p><strong><u>Crystalluria</u></strong></p><p>When tested in rats with 20, 60, 120 or 180 mg/kg of levofloxacin, crystalluria has been observed in some intravenous rat studies; urinary crystals are not formed in the bladder, being present only after micturition and are not associated with nephrotoxicity.</p><p>&nbsp;</p><p><strong><u>Cardiac Effects</u></strong></p><p>Levofloxacin exhibits a weak interaction with the human HERG channel. The IC50&nbsp;for levofloxacin in inhibiting human HERG K+&nbsp;channel is 915 mcM. At therapeutic doses of 250, 500, and 750 mg levofloxacin, the peak unbound plasma concentrations ranged from 6 mcM for a single oral levofloxacin dose of 250 mg to 12 mcM and 15 mcM for 500 and 750 mg levofloxacin doses, respectively.</p><p>&nbsp;</p><p>Studies in rabbit Purkinje fibers and studies in guinea pig right ventricular myocardium revealed no detectable effect on action potential duration with levofloxacin at concentrations up to 100 mcM.</p><p>&nbsp;</p><p>The potential for levofloxacin to induce torsades de pointes was examined in a canine model of chronic high-degree atrioventricular block. Oral administration of levofloxacin at 6 and 60 mg/kg induced no ventricular arrhythmias. Monophasic action potential duration (MAP90) was not significantly affected by levofloxacin 0.3 and 3.0 mg/kg IV.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PRINCEOXIN(levofloxacin) Tablets are available as film-coated tablets and contain the following inactive ingredients:</p><p>&nbsp;</p><p><strong>250 mg:</strong> croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, methylcellulose, stearic acid, hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyethylene glycol, titanium dioxide, red ferric oxide.</p><p>&nbsp;</p><p><strong>500 mg:</strong> croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, methylcellulose, stearic acid, hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyethylene glycol, titanium dioxide, red ferric oxide, yellow ferric oxide.</p><p>&nbsp;</p><p><strong>750 mg:</strong> croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, methylcellulose, stearic acid, hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyethylene glycol, titanium dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C, protected from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Strength</strong></p></td><td style="vertical-align:top"><p><strong>Unit<strong> </strong>Count</strong><strong> </strong><strong>or</strong><strong> </strong><strong>Fill</strong><strong> </strong><strong>Size</strong></p></td><td style="vertical-align:top"><p><strong>Container<strong> </strong>Size(s)</strong></p></td><td style="vertical-align:top"><p><strong>Description</strong></p></td></tr><tr><td style="vertical-align:top" rowspan="2"><p>250 mg</p><p>500 mg</p><p>750 mg</p></td><td style="vertical-align:top" rowspan="2"><p>5&rsquo;s</p></td><td style="vertical-align:top" rowspan="2"><p>Blisters</p></td><td style="vertical-align:top"><p>FILM PVC/PVdC CLEAR 10MIL 250/60 205MM</p></td></tr><tr><td style="vertical-align:top"><p>FOIL SILVER PLAIN 205MM 25UM</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Incorporated
150 Signet Drive, Toronto, Ontario Canada, M9L 1T9
Tel: 1‐800‐268‐4623, Fax: 1‐800‐609‐9444
www.apotex.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                03/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>